Studies on the interaction of the inhibitor of apoptosis protein Survivin with DNA-dependent protein kinase to modulate DNA double-strand break repair by Weipert, Fabian
   
  
 
 
 
 
Studies on the interaction of the inhibitor of apoptosis 
protein Survivin with DNA-dependent protein kinase to 
modulate DNA double-strand break repair 
 
 
 
Vom Fachbereich Biologie  
der Technischen Universität Darmstadt 
zur Erlangung des akademischen Grades eines  
Doctor rerum naturalium 
genehmigte Dissertation von 
M.Sc. Fabian Weipert 
aus Tübingen 
 
 
Erstgutachter: Prof. Dr. Bodo Laube 
Zweitgutachter: Prof. Dr. Markus Löbrich 
 
Tag der Einreichung: 16.04.2018 
Tag der mündlichen Prüfung: 30.05.2018 
 
Darmstadt 2018 
D 17 
 
   
 
Weipert, Fabian: Studies on the interaction of the inhibitor of apoptosis protein Survivin with 
DNA-dependent protein kinase to modulate DNA double-strand break repair 
Darmstadt, Technische Universiät Darmstadt 
Jahr der Veröffentlichung der Dissertation auf TUprints: 2018 
URN: urn:nbn:de:tuda-tuprints-74734 
Tag der mündlichen Prüfung: 30.05.2018 
 
Veröffentlicht unter CC BY-NC-ND 4.0 International 
https://creativecommons.org/licenses/ 
 
  I 
Word of Honour 
 
 
Ehrenwörtliche Erklärung: 
 
Ich erkläre hiermit ehrenwörtlich, dass ich die vorliegende Arbeit entsprechend den Regeln 
guter wissenschaftlicher Praxis selbstständig und ohne unzulässige Hilfe Dritter angefertigt 
habe.  
Sämtliche aus fremden Quellen direkt oder indirekt übernommenen Gedanken sowie 
sämtliche von Anderen direkt oder indirekt übernommenen Daten, Techniken und Materialien 
sind als solche kenntlich gemacht. Die Arbeit wurde bisher bei keiner anderen Hochschule zu 
Prüfungszwecken eingereicht. 
 
 
___________________________ 
Fabian Weipert 
 
Darmstadt, den 16.04.2018 
 
  II 
Contents 
  
WORD OF HONOUR ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  I 	
CONTENTS .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  II 	
LIST OF FIGURES .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  V 	
LIST OF TABLES .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  VII 	
LIST OF ABBREVIATIONS .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  VIII 	
1. 	 SUMMARY ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 	
2. 	 INTRODUCTION ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 	
2.1.	 CANCER ........................................................................................................................ 4	
2.2.	 DNA DAMAGE RESPONSE ................................................................................................. 5	
2.2.1.	 DNA double-strand break repair ......................................................................................... 6	
2.3.	 DNA-DEPENDENT PROTEIN KINASE ................................................................................. 10	
2.3.1.	 Characterisation of DNA-PK .............................................................................................. 10	
2.3.2.	 Role of DNA-PK in non-homologous end-joining .............................................................. 11	
2.4.	 INHIBITOR OF APOPTOSIS PROTEIN FAMILY ...................................................................... 11	
2.5.	 THE INHIBITOR OF APOPTOSIS PROTEIN SURVIVIN ............................................................ 12	
2.5.1.	 Characterisation of Survivin ............................................................................................. 12	
2.5.2.	 Survivin as a molecular target in oncology ....................................................................... 17	
2.6.	 AIM OF THE THESIS ....................................................................................................... 18	
3. 	 MATERIALS AND METHODS .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19 	
3.1.	 MATERIALS .................................................................................................................. 19	
3.1.1.	 Appliances/Instruments .................................................................................................... 19	
3.1.2.	 Consumables .................................................................................................................... 20	
3.1.3.	 Chemicals and media ........................................................................................................ 22	
3.1.4.	 Solutions and buffers ........................................................................................................ 25	
3.1.5.	 Antibodies ........................................................................................................................ 29	
3.1.6.	 Expression plasmids .......................................................................................................... 31	
3.1.7.	 Specific small interfering RNA .......................................................................................... 35	
3.1.8.	 Commercial kits ................................................................................................................ 35	
3.1.9.	 Enzymes and respective buffers ........................................................................................ 35	
3.1.10.	 Electrophoresis markers .................................................................................................. 36	
3.1.11.	 Oligonucleotides ............................................................................................................. 36	
3.1.12.	 Cells ................................................................................................................................ 39	
3.2.	 METHODS ................................................................................................................... 41	
3.2.1.	 Cell culture ....................................................................................................................... 41	
  III 
3.2.2.	 Freezing and thawing of cells ........................................................................................... 41	
3.2.3.	 Depletion of endogenous Survivin with siRNA ................................................................. 41	
3.2.4.	 Transient transfection of DNA plasmids ........................................................................... 42	
3.2.5.	 Stable transfection ............................................................................................................ 42	
3.2.6.	 Irradiation procedure ....................................................................................................... 43	
3.2.7.	 Harvesting and lysis of cells .............................................................................................. 43	
3.2.8.	 Determination of protein concentration ........................................................................... 44	
3.2.9.	 SDS polyacrylamide gel electrophoresis ........................................................................... 44	
3.2.10.	 Coomassie Blue staining ................................................................................................. 45	
3.2.11.	 Western blotting ............................................................................................................. 45	
3.2.12.	 Immunoprecipitation ...................................................................................................... 45	
3.2.13.	 Vector cloning ................................................................................................................ 46	
3.2.14.	 Production of bacterial GST fusion proteins and GST preparation ................................. 49	
3.2.15.	 GST pulldown assay ....................................................................................................... 49	
3.2.16.	 NanoLuc Binary Technology (NanoBiT®) complementation assay ................................ 50	
3.2.17.	 Förster resonance energy transfer assay ......................................................................... 51	
3.2.18.	 Immunofluorescence staining and imaging .................................................................... 52	
3.2.19.	 Homologous recombination assay .................................................................................. 53	
3.2.20.	 DNA-PK activity assay ..................................................................................................... 54	
3.2.21.	 Protein docking analysis ................................................................................................. 55	
3.2.22.	 Data analysis .................................................................................................................. 56	
4. 	 RESULTS .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57 	
4.1.	 THE IMPACT OF SURVIVIN ON THE DNA DOUBLE-STRAND BREAK REPAIR ............................. 57	
4.1.1.	 Survivin depletion impacts on the number of DNA double-strand breaks after irradiation 
with X-rays ..................................................................................................................................... 57	
4.1.2.	 Involvement of Survivin in the non-homologous end-joining repair pathway .................. 59	
4.1.3.	 Analysis of the involvement of Survivin in the homologous recombination repair pathway
 61	
4.2.	 ESTABLISHMENT OF CELL LINES, STABLY EXPRESSING A SURVIVIN-ΔXIAP DELETION MUTANT 62	
4.3.	 INTERACTION OF SURVIVIN WITH DNA-PKCS, A KEY PLAYER OF THE NON-HOMOLOGOUS END-
JOINING DNA REPAIR PATHWAY ............................................................................................... 63	
4.3.1.	 Interaction of the Survivin-ΔXIAP mutant with DNA-PKcs ............................................... 63	
4.3.2.	 Interaction of Survivin with the kinase domain (PI3K) of DNA-PKcs ................................ 65	
4.4.	 THE IMPACT OF SURVIVIN ON THE ACTIVITY OF DNA-PK .................................................. 73	
4.4.1.	 Survivin depletion modulates autophosphorylation of DNA-PKcs on serine 2056 ............ 74	
4.4.2.	 XIAP binding site of Survivin is crucial for modulation of DNA-PK kinase activity ........... 74	
5. 	 DISCUSSION ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  76 	
  IV 
6. 	 REFERENCES .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  85 	
7. 	 APPENDIX .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  101 	
7.1.	 DNA SEQUENCES ....................................................................................................... 101	
7.2.	 CURRICULUM VITAE .................................................................................................... 103	
7.3.	 OWN WORK ............................................................................................................... 104	
7.4.	 ACKNOWLEDGEMENTS ................................................................................................ 105	
  V 
List of Figures 
 
Figure 1: Schematic representation of the HR repair pathway .................................................. 7	
Figure 2: Schematic representation of the NHEJ repair pathway .............................................. 9	
Figure 3: Schematic illustration of the DNA-PKcs protein structure ........................................ 10	
Figure 4: Schematic illustration of the Survivin protein structure ........................................... 13	
Figure 5: Schematic illustration of Survivin’s role in radiation response ................................. 15	
Figure 6: Plasmid map of pEYFP-C1 (Clonetech, Mountain View, CA, USA) ........................... 31	
Figure 7: Plasmid map of pEYFP-N1 (Clonetech, Mountain View, CA, USA) .......................... 32	
Figure 8: Plasmid map of pH3FE ............................................................................................ 33	
Figure 9: Plasmid map of pGEX-5X-3 (GE Healthcare, Little Chalfont, UK) ............................ 34	
Figure 10: Treatment with Survivin-specific siRNA results in increased numbers of γH2AX and 
53BP1 foci in irradiated SW480 cells ............................................................................... 58	
Figure 11: Treatment with Survivin-specific siRNA results in increased numbers of γH2AX and 
53BP1 foci in irradiated A2780 cells ................................................................................ 59	
Figure 12: Treatment with Survivin-specific siRNA results in increased numbers of γH2AX and 
53BP1 foci in irradiated OVSAHO cells ............................................................................ 60	
Figure 13: Homologous recombination (HR) assay displays no involvement of Survivin in HR 
in SW480 cells ................................................................................................................. 61	
Figure 14: Stable transfection of colorectal cancer (SW480) and glioblastoma (LN-229) cells 
with Survivin-EGFP fusion constructs .............................................................................. 63	
Figure 15: In immunoprecipitation (IP) experiments with SW480 lysates, DNA-PKcs was 
found to precipitate with recombinant Survivin wt but not with the ΔXIAP deletion 
mutant after irradiation with 4 Gy ................................................................................... 64	
Figure 16: In immunoprecipitation (IP) experiments with LN-229 lysates, DNA-PKcs was 
found to precipitate with recombinant Survivin wt but not with the ΔXIAP deletion 
mutant after irradiation with 4 Gy ................................................................................... 64	
Figure 17: Expression of GST fusion constructs in E. coli BL21 for GST pulldown assay ......... 66	
Figure 18: GST pulldown assay in SW480 cells shows binding of Survivin to the PI3K domain 
of DNA-PKcs ..................................................................................................................... 67	
Figure 19: Schematic representation of the NanoBiT complementation assay principle ......... 68	
Figure 20: Expression of Survivin-LgBiT and Survivin-SmBiT constructs in HEK-293T cells ... 68	
Figure 21: NanoBiT complementation assay for protein-protein interaction analysis indicates 
an interaction between Survivin and the PI3K domain of DNA-PKcs ............................... 69	
  VI 
Figure 22: Schematic representation of the Förster resonance energy transfer (FRET) principle
 ........................................................................................................................................ 70	
Figure 23: Expression of CFP/YFP-Survivin/-PI3K fusion constructs in HEK-293T cells ......... 71	
Figure 24: Exemplary gating strategy for FRET interaction analyses with flow cytometry ...... 72	
Figure 25: Flow cytometry-based FRET measurements show an interaction between Survivin 
and the PI3K domain of DNA-PKcs .................................................................................. 73	
Figure 27: Autophosphorylation of serine 2056 of DNA-PKcs is modulated by Survivin ......... 74	
Figure 28: XIAP binding site deletion mutant of Survivin is not able to restore DNA-PK kinase 
activity upon knockdown of endogenous Survivin ........................................................... 75	
Figure 28: Protein docking analysis show an interaction between Survivin and DNA-PKcs .... 81	
Figure 29: Survivin as a modulator of the NHEJ double-strand break repair pathway ............ 83	
 
  VII 
List of Tables 
 
Table 1: Characteristics of primary antibodies used for western immunoblotting, 
immunoprecipitation and immunofluorescence staining ................................................. 29	
Table 2: Characteristics of secondary antibodies used for immunofluorescence staining ........ 30	
Table 3: Characteristics of secondary antibodies used for western immunoblotting ............... 30	
Table 4: Primers for cloning of the GST-PI3K construct .......................................................... 37	
Table 5: Primers for cloning of the NanoBiT® Complementation Assay constructs ................ 37	
Table 6: Primers for cloning of the FRET constructs ............................................................... 37	
Table 7: Primers used for sequencing of the cloned constructs ............................................... 38	
Table 8: Pipetting scheme for two discontinuous SDS electrophoresis gels ............................. 44	
Table 9: Standard PCR protocol for DNA amplification with PfuUltra HF ............................... 46	
Table 10: Composition of the transfection reagents for single or double transfections for the 
NanoBiT® complementation assay .................................................................................. 51	
Table 11: Composition of the single or double transfection reaction batches for FRET analysis
 ........................................................................................................................................ 52	
Table 12: Composition of the single or double transfection reactions for the homologous 
recombination assay ........................................................................................................ 53	
Table 13: Protocol for real-time PCR used for amplification of the homologous recombination 
product ............................................................................................................................ 54	
 
  VIII 
List of Abbreviations 
 
53BP1 p53-binding protein 1 
a-EJ alternative end-joining 
Amp ampicillin 
Apaf1 apoptotic protease-activating factor 1 
APC adenomatous polyposis coli gene 
APS ammonium persulfate 
ATM Ataxia telangiectasia mutated protein kinase 
ATR Ataxia telangiectasia and Rad3 related protein 
BCA bicinchoninic acid 
BER base excision repair 
BIR baculoviral IAP repeat 
BLM Blooms syndrome helicase 
bp base pairs 
BRCA1/2 breast cancer type 1/2 susceptibility protein 
BSA bovine serum albumin 
CDE cell cycle-dependent element 
CDK1 cyclin-dependent kinase 1 
CHR cell cycle genes homology region 
c-H-Ras v-Ha-ras Harvey rat sarcoma viral oncogene homologue 
c-IAP1/2 cellular-IAP1/2 
c-Myc v-myc myelocytomatosis viral oncogene homologue 
CPC chromosomal passenger complex 
Crm1 chromosome region maintenance protein 1 homolog 
Da Dalton 
DAPI 4′.6-Diamidin-2-phenylindol 
DCA dichloroacetic acid 
DDR DNA damage response 
DHJ double Holliday junction 
  IX 
D-loop displacement loop 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNA-PKcs DNA-dependent protein kinase, catalytic subunit 
dNTP deoxynucleotides 
DSB DNA double-strand break 
DTT dithiothreitol 
ECFP enhanced cyan fluorescent protein 
ECL enhanced chemiluminescent 
EDTA ethylenediaminetetraacetic acid 
EGFP enhanced green fluorescent protein 
E. coli Escherichia coli 
ESCC esophageal squamous cell carcinoma 
Exo1 Exonuclease1 
EYFP enhanced yellow fluorescent protein 
FAK focal adhesion kinase 
FAT FRAP, ATM, TRRAP domain 
FATC C-terminal of FAT 
FBS fetal bovine serum 
FOXO1 forkhead box O1 
FRET Förster resonance energy transfer 
GST glutathione S-transferase 
Gy Gray 
HBXIP hepatitis B X-interacting protein 
HEAT huntingtin, elongation factor 3, regulatory subunit A of PP2A, TOR1 
HIF-1α hypoxia inducible factor 1α 
HR homologous recombination 
HRP horse radish peroxidase 
Hsp heat shock protein 
IAP inhibitor of apoptosis 
  X 
IgG immunglobulin G 
INCENP inner centromere protein 
IP immunoprecipitation 
IR ionizing radiation  
Kan kanamycin 
kb kilo base pairs 
Lig4 DNA ligase IV 
MALT mucosa-associated lymphoid tissue 
MCS multiple cloning site 
MDC1 mediator of DNA damage checkpoint protein 1 
MMEJ microhomology-mediated end-joining 
MOPS 3-(N-morpholino)propanesulfonic acid 
MRN Mre11/Rad50/Nbs1 
MTOC microtubule organizing centres 
mTOR mammalian target of rapamycin 
Neo neomycin 
NER nucleotide excision repair 
NES nuclear export signal 
NLS nuclear localisation signal 
NF-κB nuclear factor-kappa B 
NHEJ non-homologous end-joining 
Notch neurogenic locus notch homologue 
NP-40 Nonidet P-40 
NSCLC non-small cell lung cancer 
ori origin of replication 
Parp1 poly (ADP-ribose) polymerase 1 
PBS Dulbecco’s Phosphate Buffered Saline 
PCR polymerase chain reaction 
PI3K phosphatidylinositol-3-kinase 
PIKK phosphatidylinositol 3-kinase-related kinases 
PKA protein kinase A 
  XI 
Plk1 polo-like kinase 1 
PNK polynucleotide kinase 
PTEN phosphatase and tensin homologue deleted from chromosome ten 
RING really interesting new gene 
RIPA radio-immunoprecipitation assay 
RNA ribonucleic acid 
ROS reactive oxygen species 
RPA replication protein A 
RPMI Roswell Park Memorial Institute 
RT room temperature 
S, Ser serine 
SDS sodium dodecylsulfate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM standard error of the mean 
SIRT1 silent mating type information regulation 2 homologue 2 
Smac second mitochondria derived activator of caspase 
Src c-Sarcoma 
SEM standard error of the mean 
STAT3 signal transduction and activator of transcription 3 
T, Thr threonine 
TAE Tris acetate EDTA 
TBS Tris-buffered saline 
TBS-T TBS-Tween 20 
TCA trichloroacetic acid 
TCF4 β-catenin/transcription factor 4 
TEMED tetramethylethylenediamin 
TNF-α tumour necrosis factor-α 
TRAIL TNF-related apoptosis-inducing ligand 
Tris tris hydroxymethyl aminomethane 
UTR untranslated region 
UV ultraviolet 
  XII 
WNT wingless-related integration site 
wt wild type 
XAF1 XIAP-associating factor 1 
XIAP X-linked inhibitor of apoptosis protein 
XLF XRCC4-like factor 
XRCC1/2/4 X-ray cross-complementing protein 1/2/4 
 
 Summary 1 
1. Summary 
During the last years, the ability of tumour cells to evade apoptosis was considered to be an 
important mechanism to develop resistance against tumour therapies. In this context, 
members of the inhibitor of apoptosis protein (IAP) family gained increasing attention. 
Survivin, the smallest member of the IAP family, is a functionally unique protein that is 
involved in a variety of molecular mechanisms and cellular networks including cell 
proliferation, regulation of apoptosis and metastasis formation. Furthermore, an 
overexpression of Survivin in the tumour tissue was correlated with tumour progression as 
well as a decreased survival of the patients. Besides inhibition of apoptosis and its role as a 
member of the chromosomal passenger complex, Survivin was also found being accumulated 
in the nucleus after irradiation. That accumulation was linked to a modulation of DNA 
double-strand break repair due to its interaction with DNA repair factors such as the catalytic 
subunit of DNA-dependent protein kinase (DNA-PKcs).  
The aim of this thesis was to gain further insight on the molecular mechanisms facilitating a 
Survivin-mediated regulation of DNA repair by characterising the interaction between 
Survivin and DNA-PKcs, a major enzyme in the non-homologous end-joining (NHEJ) DNA 
double-strand break repair pathway, in more detail. 
Docking of Survivin wild type (wt) and a X-linked IAP (XIAP) binding site deletion mutant 
(ΔXIAP) of Survivin to DNA-PKcs was evaluated in colorectal cancer SW480 and glioblastoma 
LN-229 cells via immunoprecipitation experiments. These experiments indicated that 
recombinant Survivin (wt) was able to co-immunoprecipitate with DNA-PKcs in both lines 
while the ΔXIAP mutant of Survivin did not show complexation to DNA-PKcs. In case of the 
Aurora-B kinase it has been reported that Survivin stimulates Aurora-B kinase activity by 
binding to the catalytic domain. In analogy, an interaction of Survivin with the kinase domain 
of DNA-PKcs (PI3K) was analysed by different methods, including GST pulldown assay, 
NanoLuc Binary Technology (NanoBiT®) complementation assay and flow cytometry-based 
Förster resonance energy transfer (FRET). All of these methods confirmed an interaction 
between Survivin and the PI3K domain of DNA-PKcs, indicating that Survivin is binding 
directly to the kinase domain but not to other domains like the HEAT1 and FATC domain. 
Additionally, functional analysis, such as autophosphorylation of serine 2056 of DNA-PKcs, 
revealed a decreased DNA-PK activity after Survivin knockdown in both SW480 and LN-229 
cells. Finally, attenuation of endogenous Survivin in the ΔXIAP mutant of Survivin resulted in 
a decreased DNA-PK activity measured by SignaTECT kinase assay, while recombinant 
Survivin (wt) rescued DNA-PK activity following irradiation with 4 Gy. 
In conclusion these findings for the first time indicate that Survivin not only interacts with 
DNA-PKcs but directly binds to its kinase domain. Thus, it modulates DNA-PKcs kinase activity 
and as a consequence repair of radiation induced DNA double-strand breaks. These results 
add a further facet to the plethora of functions exerted by the nodal protein Survivin in the 
cellular radiation response in cancer cells. 
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Zusammenfassung 
In den vergangenen Jahren wurde die Fähigkeit von Tumorzellen Apoptose zu umgehen bzw. 
zu vermeiden als zentraler Mechanismus einer Therapieresistenz erkannt. In diesem 
Zusammenhang gewannen auch Vertreter der inhibitor of apoptosis protein (IAP) Familie 
immer mehr an Bedeutung. Dabei spielt unter anderem Survivin, der kleinste Vertreter dieser 
Proteinfamilie, eine bedeutende Rolle aufgrund der universellen Überexpression in 
Tumorzellen. Survivin ist an einer Vielzahl molekularer Mechanismen und zellulärer 
Netzwerke wie beispielsweise Zellproliferation, intrazellulärer Signaltransduktion, 
Apoptoseregulation und Metastasierung beteiligt. Darüber hinaus konnte eine Überexpression 
von Survivin mit der Tumorprogression und einem schlechteren Überleben der Patienten 
korreliert werden. Neben der Hemmung von Apoptose und seiner Rolle in der 
Zellzyklusregulation ist Survivin ebenfalls bekannt dafür nach Bestrahlung im Nukleus zu 
akkumulieren. Dies steht im Zusammenhang mit der Rolle von Survivin bei der Regulation 
der DNA-Reparatur als Teil der zellulären Strahlenantwort.  
In dieser Arbeit sollte der genaue molekulare Mechanismus einer Survivin-vermittelten 
Regulation der DNA-Reparatur untersucht werden. Dafür wurde die Interaktion zwischen 
Survivin und der katalytischen Untereinheit der DNA-abhängigen Proteinkinase (DNA-PKcs), 
einem wichtigen Faktor im non-homologous end-joining (NHEJ) genauer untersucht. Beim 
NHEJ handelt es sich um einen der beiden Hauptwege der DNA-Doppelstrangbruchreparatur.  
Um die Interaktion zwischen Survivin und DNA-PKcs genauer zu verstehen, wurde die 
Bindung einer Deletionsmutante der X-linked IAP-Bindestelle (ΔXIAP) von Survivin an DNA-
PKcs mittels Immunpräzipitation untersucht. Hierbei zeigte sich sowohl in kolorektalen 
SW480 Karzinomzellen als auch in LN-229 Glioblastomzellen, eine Bindung des Survivin-
Wildtyps an DNA-PKcs, während die Deletionsmutante der XIAP Bindestelle von Survivin 
nicht mehr mit DNA-PKcs präzipitieren konnte. Im Falle der Aurora-B Kinase ist bekannt, dass 
Survivin die Kinaseaktivität durch das Binden an deren katalytische Domäne stimuliert. Aus 
diesem Grund sollte im weiteren Verlauf dieser Studie eine Interaktion von Survivin mit der 
Kinasedomäne PI3K von DNA-PKcs mittels verschiedener Methoden wie GST pulldown Assay, 
NanoLuc Binary Technology (NanoBiT®) Komplementationsassay und Förster-
Resonanzenergietransfer (FRET) am Durchflusszytometer untersucht werden. Durch alle 
verwendeten Analysemethoden konnte eine eindeutige Interaktion zwischen Survivin und der 
PI3K-Domäne, nicht jedoch mit anderen Domänen wie HEAT1 und FATC gezeigt werden, was 
auf eine direkte Bindung Survivins an die Kinasedomäne von DNA-PKcs schließen lässt. 
Zusätzlich zeigten funktionelle Analysen der Interaktion zwischen Survivin und DNA-PKcs, 
wie zum Beispiel die Detektion der Autophosphorylierung von DNA-PKcs an Serin 2056, eine 
verminderte Kinaseaktivität von DNA-PK nach Herunterregulation von Survivin in 
kolorektalen SW480 Karzinomzellen und LN-229 Glioblastomzellen. Eine Herunterregulation 
des endogenen Survivins in ΔXIAP-exprimierenden Zellen und Bestrahlung mit 4 Gy zeigte 
eine verminderte DNA-PK-Aktivität im SignaTECT Kinase-Assay, wohingegen der 
rekombinante Survivin Wildtyp die Kinaseaktivität wiederherstellen konnte.  
In dieser Studie konnte zum ersten Mal gezeigt werden, dass Survivin nicht nur mit DNA-PKcs 
interagiert, sondern direkt an dessen Kinasedomäne bindet. Durch diese Interaktion moduliert 
Survivin die Kinaseaktivität von DNA-PKcs und damit die Reparatur von strahleninduzierten 
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DNA-Doppelstrangbrüchen. Alles in allem wird Survivin einmal mehr seiner Rolle als 
Knotenpunkt-Protein in der zellulären Strahlenantwort gerecht.  
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2. Introduction 
 
2.1. Cancer 
With more than 8.8 million deaths, cancer was the second most prevalent cause of death 
worldwide in 2015. Almost every sixth case of death can be traced back to cancer (WHO, 
2018). The number of cancer cases is still increasing due to growth and increasing age of the 
population (Torre et al., 2015). There are a variety of reasons for the development of cancer, 
although one third of all cancers are caused by behavioural and dietary reasons, e.g. obesity, 
low fruit and vegetable consume, lack of physical activity, smoking or alcohol abuse (Risk 
Factors Collaborators, 2016; Torre et al., 2015; WHO, 2018). Mainly cancer starts with 
genetic damage. One can discriminate between dominant damage targeting proto-oncogenes 
and recessive damage, which is targeting tumour suppressor genes or anti-oncogenes. 
Dominant damage usually leads to a gain of function, whereas recessive damage results in a 
loss of function. The resulting activation of oncogenes and the inactivation of tumour 
suppressor genes, respectively, is one basis of the transformation of a normal cell into a 
tumour cell (Bishop, 1987, 1991). This can be caused by mutations of genes, chromosome 
aberrations (Bishop, 1987; Holliday, 1979) or hypo-/hypermethylation of CpG islands in 
promoter regions (Jones and Laird, 1999). However, a single change within a cell is not 
sufficient for the development of a solid malignancy, instead multiple mutations are necessary 
(Kinzler and Vogelstein, 1996).  
Hanahan and Weinberg first introduced the hallmarks of cancer in 2000. The hallmarks of 
cancer describe the acquired functional capabilities of (nearly) all human cancers during their 
development. These capabilities are self-sufficiency in growth signals, insensitivity to anti-
growth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis as 
well as tissue invasion and metastasis (Hanahan and Weinberg, 2000). In 2011 Hanahan and 
Weinberg added four additional capabilities to the hallmarks of cancer: Genomic instability 
and mutation can be selectively advantageous to cells, which leads to their dominance in a 
local tissue environment and therefore benefits tumour progression. The second one is 
tumour-promoting inflammation, describing an infiltration of the tumour by cells of the 
immune system. This tumour-associated inflammatory response can supply the tumour 
development with bioactive molecules like growth factors, enhancing multiple hallmark 
capabilities (Hanahan and Weinberg, 2011). Two other emerging hallmarks are the 
deregulation of cellular energetics, which describes the adjustments of the cancer cells in their 
energy metabolisms in order to produce enough energy for cell growth and division, and the 
ability of tumour cells to avoid destruction by the immune system (Hanahan and Weinberg, 
2011). In contrast to the earlier view of a tumour as a collection of homogeneous cancer cells, 
they are now considered as complex organs. In order to understand the biology of tumours, 
one has to study the individual cell types within the tumour as well as its microenvironment. 
This tumour microenvironment contains a variety of different cell types, e.g. cancer stem cells, 
immune cells, pericytes, endothelial cells and cancer-associated fibroblasts (Hanahan and 
Weinberg, 2011). 
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Therapeutic approaches of cancer diseases vary depending on the tumour entity as well as 
grade and stage of the tumour. More than 60% of all cancer patients receive radiotherapy 
during their treatment. It can be used in adjuvant and neoadjuvant settings and in most cases 
radiotherapy is used in a multimodal combination together with chemotherapy and the 
surgical resection of the tumour. Due to new technologies, radiotherapy has strongly 
improved in the last years but also approaches combining tumour therapy with molecularly 
designed agents targeting the hallmarks of cancer have further improved the clinical outcome 
of the patients (Orth et al., 2014). Another upcoming therapy approach is the combined 
treatment of the above-mentioned treatments with immunotherapeutic strategies aiming for a 
stimulation of anti-tumour immune response, which can lead to improved tumour control 
(Scheithauer et al., 2014).  
 
2.2. DNA damage response 
The main goal for every living organism is to deliver intact and unchanged genetic material to 
its descendants. The genomic integrity is threatened by a permanent occurrence of DNA 
damage. This DNA damage can be caused by endogenous factors like replication errors or 
endogenously generated reactive oxygen species (ROS) as well as exogenous factors, for 
instance environmental caused DNA damage by ultraviolet (UV) light or ionizing radiation 
(IR). There are a variety of DNA damage lesions, of which the DNA double-strand break 
(DSB) is the most severe one (Jackson and Bartek, 2009; Khanna and Jackson, 2001). These 
breaks are more difficult to repair and even though occurring in low numbers, DSB can cause 
chromosomal aberrations or loss of genetic information what can lead to tumourigenesis 
(Khanna and Jackson, 2001).  
In order to prevent transforming into a tumour cell after DNA damage, cells have developed 
highly coordinated mechanisms including cell cycle checkpoints, DNA repair and apoptosis, 
together called the DNA damage response (DDR) (Jackson and Bartek, 2009). To prevent the 
cells from progressing into synthesis or mitosis with damaged DNA or not fully replicated 
chromosomes, the progression of the cells to the next cell cycle phase can be arrested by the 
activation of cell cycle checkpoints. This delay enables the cell to repair DNA damage before 
progressing in the cell cycle (de la Torre-Ruiz and Lowndes, 2000). Depending on the existing 
DNA damage as well as the cell cycle phase, DNA repair pathways such as base excision repair 
(BER), nucleotide excision repair (NER), homologous recombination (HR) and non-
homologous end-joining (NHEJ) are used to repair the damage (Branzei and Foiani, 2008; 
Ciccia and Elledge, 2010). If the DNA is irreparably damaged, the cell can induce the 
programmed cell death apoptosis in order to prevent the organism from mutations and 
tumour formation (Sancar et al., 2004). These DDR mechanisms are working hand in hand 
and their correct functioning is crucial for maintaining the genomic integrity of a cell (Sancar 
et al., 2004).  
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2.2.1. DNA double-strand break repair 
The two major pathways for the repair of DNA DSBs are homologous recombination (HR) and 
non-homologous end-joining (NHEJ). HR is a rather slow but error-free DNA repair pathway 
that does not lose any genetic information. Since it uses homologous sister chromatids as a 
template for the re-synthesis of the damaged DNA, it can only take place in S and G2 phase 
when the sister chromatids are present (Beucher et al., 2009; van Gent et al., 2001). In 
contrast, NHEJ is a fast repair pathway that is not restricted to a specific phase of the cell 
cycle. Nevertheless the mechanism is error-prone and often results in loss of genetic 
information or chromosomal aberrations (Branzei and Foiani, 2008; Pfeiffer et al., 2004; 
Riballo et al., 2004). DNA damage caused by ionizing radiation in G2 phase is mainly repaired 
by NHEJ (80%) whereas HR repairs approximately 20% of the DSBs (Beucher et al., 2009). 
However, HR preferably repairs complex DNA damages induced by e.g. carbon ions in S and 
G2 phase (Shibata et al., 2011). 
In the presence of DSBs, the MRN (Mre11/Rad50/Nbs1) complex binds to the break side 
leading to a recruitment of the ataxia telangiectasia mutated (ATM) protein kinase (Uziel et 
al., 2003) and its activation via autophosphorylation (Bakkenist and Kastan, 2003). Following 
activation, ATM phosphorylates the H2A histone variant H2AX to form γH2AX, which is 
considered one of the earliest DSB signalling markers (Rogakou et al., 1998). Subsequently, 
γH2AX enables the recruitment of other DNA repair factors, such as p53-binding protein 1 
(53BP1), mediator of DNA damage checkpoint protein 1 (MDC1), breast cancer type 1 
susceptibility protein (BRCA1) etc. to the DSB (Celeste et al., 2002; Lou et al., 2006). 
 
Homologous recombination 
A model for HR was introduced by Robin Holliday and describes the concept of exchanging 
genetic information between two homologous chromosomes via the formation of so called 
Holliday junctions. More specifically, HR uses the undamaged sister chromatid as a template 
for repair by a direct interaction of the two sister chromatids. For that reason, HR is restricted 
to S and G2 phase of the cell cycle when a sister chromatid is present (San Filippo et al., 
2008). According to the double Holliday junction (DHJ) model, HR can be divided into 
multiple steps. After the induction of a DSB, the 5’ ends of the DSB are degraded (resection) 
to generate single stranded DNA. After finding a homologous region, the single-stranded DNA 
is invading the homologous DNA sequence, leading to the formation of a displacement loop 
(D-loop). Then, DNA synthesis is taking place with the homologous DNA sequence as 
template and thereby DHJ are formed. In the last step, the DHJ are dissolved again, what 
potentially leads to DNA crossover structures (San Filippo et al., 2008).  
A variety of proteins are involved in the different steps of HR. In mammalian cells, resection is 
initialized by the MRN complex together with CtIP and processed in 3’-5’ direction (Garcia et 
al., 2011; Makharashvili et al., 2014; Symington and Gautier, 2011) as well as the nucleases 
DNA2 (together with Blooms syndrome helicase, BLM) and Exonuclease1 (Exo1) in 5’-3’ 
direction (Bolderson et al., 2010; Zhu et al., 2008). The generated single stranded DNA is 
covered by replication protein A (RPA) leading to a recruiting of Rad51 by Breast cancer type 
2 susceptibility protein (BRCA2) to the resected DNA regions (Sorensen et al., 2005). Rad51 
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together with Rad54 are then catalysing the search for homology and the invasion of the 
homologous DNA strand (Baumann et al., 1996; Renkawitz et al., 2014). After Rad51 has 
been removed, synthesis of the new DNA can be started (Terasawa et al., 2007). The process 
ends by dissolution of DHJ (San Filippo et al., 2008). A schematic overview of the HR repair 
pathway is shown in Figure 1. 
 
Figure 1: Schematic representation of the HR repair pathway. The first step of HR is resection, which is 
initialized by the MRN complex together with CtIP as well as the nucleases DNA2 (together with Blooms 
syndrome helicase, BLM) and Exo1 (Exonuclease 1). The generated single stranded DNA is covered by 
RPA (replication protein A) followed by recruitment of Rad51 by BRCA2 (Breast cancer type 2 
susceptibility protein) to the resected DNA regions. Rad51 together with Rad54 are then catalysing the 
search for homology and the invasion of the homologous DNA strand. Following DNA synthesis, the 
process ends by dissolution of DHJ (double Holliday junctions). (Figure modified according to (Beucher 
et al., 2009)) 
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Non-homologous end-joining 
Non-homologous end-joining is the predominant pathway for the repair of DSB in mammalian 
cells. This end-joining repair can be further divided into the canonical non-homologous end-
joining (NHEJ) and alternative end-joining (a-EJ) also called microhomology-mediated end-
joining (MMEJ). As suggested by their terms, NHEJ and MMEJ require no or very little 
homologous sequences, instead they are directly ligating the two DSB ends without the need 
of a sister chromatid. Therefore, NHEJ and MMEJ are independent of the cell cycle phase 
(Ranjha et al., 2018).  
During the NHEJ, the Ku70/80 heterodimer binds to the broken DNA ends and recruits the 
catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) generating the DNA-PK 
holoenzyme (Jette and Lees-Miller, 2015). Ligation of the compatible DNA ends is performed 
by a complex of DNA ligase IV (Lig4), X-ray cross-complementing protein 4 (XRCC4) and 
XRCC4-like factor (XLF). Human PAXX, a XRCC4 and XLF paralog, is interacting with Ku in 
order to stabilize the repair machinery (Iliakis et al., 2015; Mahaney et al., 2009; Ochi et al., 
2015). Depending on the source of DNA damage, DNA ends are not compatible and cannot be 
ligated until processed. IR, for instance, often induces DNA ends containing damaged bases 
and/or backbone sugars and these must be processed before ligation. This process is executed 
by the nuclease Artemis, the DNA polymerases Pol γ and Pol λ or the polynucleotide kinase 
(PNK) (Iliakis et al., 2015; Lieber, 2010; Mahaney et al., 2009). A schematic overview of the 
NHEJ procedure is depicted in Figure 2. 
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Figure 2: Schematic representation of the NHEJ repair pathway. Ku70/80 heterodimer binds to the 
broken DNA ends and recruits DNA-PKcs (DNA-dependent protein kinase, catalytic subunit). After 
minimal processing of the DNA ends by the nuclease Artemis, ligation is performed by a complex of Lig4 
(DNA ligase IV), XRCC4 (X-ray cross-complementing protein 4) and XLF (XRCC4-like factor). (Figure 
modified according to (Beucher et al., 2009)) 
 
MMEJ is another very fast DNA DSB repair pathway that operates as a backup to the 
canonical NHEJ or HR in G2 phase cells. However, this backup comes at the cost of increased 
formation of chromosome translocations (Iliakis et al., 2015). There are a variety of proteins 
involved in MMEJ, including poly (ADP-ribose) polymerase 1 (Parp1), Lig1 and Lig3, XRCC1 
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and Histone H1. CtIP and Mre11 are involved in DNA end resection. Polymerase θ is 
promoting MMEJ in a Parp1 dependent manner (Iliakis et al., 2015).  
 
2.3. DNA-dependent protein kinase 
 
2.3.1. Characterisation of DNA-PK 
Anderson and colleagues first described a human DNA-activated protein kinase in 1985 
(Walker et al., 1985). This serine/threonine protein kinase consists of a catalytic subunit 
(DNA-PKcs, 470 kDa), encoded by the PRKDC gene, and the heterodimer Ku70/80 (≈
150 kDa) (Collis et al., 2005; Goodwin and Knudsen, 2014; Jette and Lees-Miller, 2015). 
Along with ATM and Ataxia telangiectasia and Rad3 related protein (ATR), DNA-PKcs belongs 
to the phosphatidylinositol 3-kinase-related kinases (PIKK), a sub-family of the 
phosphatidylinositol-3-kinase (PI3K) group (Collis et al., 2005; Hill and Lee, 2010; Shiloh, 
2003). DNA-PKcs consists of a large N-terminal α-helical region including the HEAT 
(huntingtin, elongation factor 3, regulatory subunit A of PP2A, TOR1) repeats and the DNA 
interacting region, as well as a C-terminal region including the Ku interacting region and the 
FAT (FRAP, ATM, TRRAP), kinase and FATC (C-terminal of FAT) domain (Figure 3) (Jette 
and Lees-Miller, 2015). The HEAT repeats probably mediate protein-protein interactions 
(Andrade and Bork, 1995; Brewerton et al., 2004; Jiang et al., 2006) and facilitate bending to 
allow folding of the polypeptide chain into a hollow circular structure (Sibanda et al., 2010), 
whereas the functions of the FAT and FATC domains remain unclear. Though it is presumed, 
that the two domains are interacting, since they always co-occur (Bosotti et al., 2000) and 
that the FATC domain is required for kinase activity (Beamish et al., 2000). The amino acid 
sequence also contains multiple phosphorylation sites including the PQR cluster and the 
ABCDE cluster (Figure 3) (Cui et al., 2005; Meek et al., 2007). ATM and ATR primarily target 
the ABCDE cluster with the threonine (Thr, T) 2609 phosphorylation site in response to DSBs 
and replication stress. However, serine (Ser, S) 2056 is an autophosphorylation site in 
response to DSBs (Davis et al., 2014).  
 
Figure 3: Schematic illustration of the DNA-PKcs protein structure. This illustration shows the functional 
domains of DNA-PKcs, the phosphorylation clusters PQR and ABCDE and the binding region for the 
heterodimer Ku70/80. HEAT (huntingtin, elongation factor 3, regulatory subunit A of PP2A, TOR1); FAT 
(FRAP, ATM, TRRAP); PI3K: kinase domain; FATC (C-terminal of FAT). (Figure modified according to 
(Jette and Lees-Miller, 2015)) 
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2.3.2. Role of DNA-PK in non-homologous end-joining 
The holoenzyme DNA-PK is the key enzyme of the NHEJ DNA DSB repair pathway. In the first 
step that triggers NHEJ, the heterodimer Ku70/80 binds to the break ends due to its high 
affinity to DNA ends (Critchlow and Jackson, 1998; Weterings and van Gent, 2004). Ku70/80 
acts as a nodal point where the nuclease, polymerases and the ligase of the NHEJ can bind 
(Lieber, 2008). The recruitment of DNA-PKcs by Ku is DNA-dependent and in order to 
facilitate the recruitment of DNA-PKcs to the break, the Ku molecule induces an inward 
translocation (Lieber, 2008). This holoenzyme of Ku and DNA-PKcs is forming a DNA-binding 
tunnel that holds the broken DNA to protect it from unnecessary processing (Yin et al., 2017) 
but allows necessary modifications for the ligation (Lieber, 2010; Mahaney et al., 2009; 
Weterings and van Gent, 2004). The accumulation of DNA-PKcs at the break site is not 
influenced by its kinase activity or phosphorylation status, although an impairment of both 
leads to a deficient repair (Uematsu et al., 2007). Altogether DNA-PKcs has very limited 
kinase activity in the absence of Ku and DNA (Davis et al., 2014) and its function in NHEJ is 
tightly linked to its kinase activity (Jette and Lees-Miller, 2015). 
DNA-PKcs can phosphorylate all of the NHEJ factors, including Ku, XRCC4, Lig4 and XLF in 
vitro, interestingly though none of these phosphorylations are actually required for NHEJ 
(Davis et al., 2014). However, phosphorylation of the Thr2609 cluster and 
autophosphorylation of Ser2056 are important for the execution of NHEJ. Upon ablation of 
these phosphorylation sites, cells end up with severe radiosensitization and less efficient NHEJ 
repair in vitro (Davis et al., 2014). On the other hand, autophosphorylation may also lead to a 
loss of kinase activity and a dissociation of DNA-PKcs from Ku (Chan and Lees-Miller, 1996; 
Merkle et al., 2002). A model by Uematsu and colleagues proposed that autophosphorylation 
of DNA-PKcs is required for destabilization of the protein-DNA complex to make the DNA ends 
accessible which is important to facilitate ligation of the DNA strands (Uematsu et al., 2007).  
 
2.4. Inhibitor of apoptosis protein family 
In 1993 an apoptosis inhibiting baculovirus gene was discovered in virally infected Spodoptera 
frugiperda insect cells (Crook et al., 1993). Since then cellular homologs have been discovered 
in yeast, nematodes, flies and higher vertebrates (Srinivasula and Ashwell, 2008). These 
members of the inhibitor of apoptosis (IAP) protein family are characterised by the existence 
of one, two or three baculoviral IAP repeat (BIR) motifs at their N-terminus. The BIR motif is 
a sequence of approximately 70 amino acids including the signature sequence CX2CX16HX6C 
with C=cysteine, H=histidine and X=any amino acid. It folds as three-stranded β-sheets 
surrounded by four α-helices (Hinds et al., 1999; Sun et al., 1999; Sun et al., 2000; Verdecia 
et al., 2000), forming a hydrophobic core. At the centre of this core is a zinc ion, which is 
coordinated by cysteine and histidine residues (Srinivasula and Ashwell, 2008). The BIR 
domains function as mediators of protein-protein interactions, whereby the presence of more 
copies per molecule can increase the affinity for the interaction (Srinivasula and Ashwell, 
2008). Regarding this, it is also known that the members of the IAP protein family bind to 
each other via their BIR domains. For example, the BIR domain of Survivin and two BIR 
domains of X-linked inhibitor of apoptosis protein (XIAP) are responsible for the formation of 
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a complex with increasing stability against proteasomal degradation, which enables them to 
inhibit apoptosis (Dohi et al., 2004; Srinivasula and Ashwell, 2008). In addition to the BIR 
domain, the majority of IAPs contain another domain that is widely distributed, the RING 
(really interesting new gene) domain. It contains two zinc ions that are coordinated by six or 
seven cysteines and one or two histidines (Weissman, 2001). RING domains can catalyse the 
transfer of ubiquitin to target proteins in conjunction with ubiquitin activating enzyme (E1) 
and ubiquitin conjugating enzyme (E2) (Lorick et al., 1999) and by providing ubiquitin 
protein ligase (E3) activity (Srinivasula and Ashwell, 2008).  
The functions of IAPs go beyond inhibiting apoptosis. They are also known to be involved in 
mitotic chromosome segregation, cellular morphogenesis, copper homeostasis and 
intracellular signalling. The different functions are not only depending on the respective 
domains but also on changes in their expression level as well as on posttranslational 
modifications (Srinivasula and Ashwell, 2008). In particular, phosphorylation of IAPs can 
influence their stability, localisation within the cell and interactions with other proteins 
(Kuranaga et al., 2006; Oshima et al., 2006; Samuel et al., 2005). Interactions among IAPs 
can also affect their expression levels (Arora et al., 2007; Conze et al., 2005; Dohi et al., 
2004; Silke et al., 2005).  
As inhibition of apoptosis plays a major role in the formation of cancer by enabling survival in 
delicate conditions, it is not surprising that IAPs have been found to be overexpressed in many 
different tumour entities. For instance, Survivin has been shown to be highly expressed in 
most hematologic and solid human tumours (Altieri, 2003b; Miura et al., 2011) and elevated 
levels are associated with a poor prognosis of patients. This led to the hypothesis, that an 
overexpression of IAPs might comprise an oncogenic event (Altieri, 2003b; Duffy et al., 2007). 
Besides Survivin also other IAPs play a role in mammalian cancers: cellular-IAP1 (c-IAP1) 
promotes carcinogenesis (Hunter et al., 2007; Zender et al., 2006) and c-IAP2 is correlated 
with mucosa-associated lymphoid tissue (MALT) lymphoma (Inagaki, 2007). In addition to 
overexpression of IAPs to evade apoptosis, tumour cells can also down-regulate factors like 
XIAP-associating factor 1 (XAF1) that suppresses the caspase-inhibitory activity of XIAP 
(Liston et al., 2001; Plenchette et al., 2007).  
The participation of IAPs in tumourigenesis by helping the malignant cell to avoid apoptosis, 
together with the discovery of IAP-regulating proteins has put this protein family in the focus 
of many research groups aiming for IAP-targeting strategies in order to target their function to 
improve cancer therapy (Wright and Duckett, 2005).  
 
2.5. The inhibitor of apoptosis protein Survivin 
 
2.5.1. Characterisation of Survivin 
Survivin was first described by Ambrosini and colleagues in 1997. It was found to have a BIR 
domain and therefore was dedicated to the inhibitor of apoptosis protein family. The human 
BIRC5 gene encodes the Survivin protein with 142 amino acids and with 16.5 kDa it is the 
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smallest member of the IAP protein family (Ambrosini et al., 1997). Survivin can be organized 
as a monomer (Altieri, 2010; Bourhis et al., 2007) or a stable homodimer (Chantalat et al., 
2000; Verdecia et al., 2000). In contrast to other IAP members, Survivin has only one BIR 
domain and is lacking the RING domain (Ambrosini et al., 1997; Verdecia et al., 2000). At its 
C-terminus Survivin has an extended α-helical coiled-coil domain (Ambrosini et al., 1997). 
Besides, Survivin contains different phosphorylation and protein binding sites, enabling 
interactions with a large numbers of different protein partners and being involved in multiple 
activities (Colnaghi and Wheatley, 2010; Dohi et al., 2007; O'Connor et al., 2002; Wheatley et 
al., 2007) (Figure 4).  
 
Figure 4: Schematic illustration of the Survivin protein structure. The illustration shows functional 
domains, binding sites and phosphorylation sites of Survivin. INCENP: inner centromere protein; XIAP: 
X-linked inhibitor of apoptosis protein; Smac: Second mitochondria-derived activator of caspase; Hsp90: 
Heat shock protein 90; NES: nuclear export signal; S20: serine 20; T34: threonine 34; T117: threonine 
117. (Figure modified according to (Rodel et al., 2011)) 
 
Survivin was first described as a bifunctional protein involved in apoptosis and cell division 
(Altieri, 2003a; Li et al., 1998). Nowadays it is known to be a multifunctional protein, 
interacting with a variety of proteins in order to coordinate its function within different 
cellular processes (Figure 5).  
When inhibiting apoptosis, Survivin, in line with most IAPs, does not bind directly to caspases 
(Srinivasula and Ashwell, 2008). Although the exact mechanism of apoptosis inhibition by 
Survivin is not entirely clear, it is believed that apoptosis inhibition is induced by a complex 
formation of XIAP (which can bind to caspases) and Survivin (Dohi et al., 2004). In order to 
form this complex, the residues 15-38 of the Survivin BIR domain (Dohi et al., 2007) interact 
with BIR1 and BIR3 of XIAP (Dohi et al., 2004). The Survivin-XIAP complex promotes both, 
Survivin and XIAP stability against proteasomal degradation leading to increased suppression 
of caspase-9 activity (Dohi et al., 2004). Other than that, Survivin binds to hepatitis B X-
interacting protein (HBXIP) and although neither of the two proteins can interact with 
caspases individually, the complex is able to bind pro-caspase-9 in order to suppress apoptosis 
by preventing its recruitment to apoptotic protease-activating factor 1 (Apaf1) (Marusawa et 
al., 2003). Survivin localised in the mitochondria was found to be interacting with second 
mitochondria derived activator of caspase (Smac). Through binding of Smac, IAPs are losing 
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their inhibitory activity because they can no longer bind to caspase-9 leading to an activation 
of the latter (Du et al., 2000).  
Apart from inhibiting apoptosis, the Survivin-XIAP complex is further participating in 
intracellular signalling pathways. The complex is directly involved in the activation of the 
transcription factor nuclear factor-kappa B (NF-κB), which leads to an increased transcription 
of the extracellular matrix protein fibronectin. The latter engages β1 integrins at the cell 
surface and activation of the cell motility kinases, proto-oncogene c-Sarcoma (Src) and focal 
adhesion kinase (FAK). This leads to increased tumour cell migration, invasion and metastatic 
dissemination (Mehrotra et al., 2010). 
In the nucleus, Survivin, together with the mitotic kinase Aurora-B, Borealin and the inner 
centromere protein (INCENP), acts as a member of the chromosomal passenger complex 
(CPC) (Gassmann et al., 2004; Honda et al., 2003) (Figure 5). The CPC is essential for the 
coordination of proper chromosome segregation and cytokinesis (Lens et al., 2006; Ruchaud 
et al., 2007; Yang et al., 2004). Survivin is concentrated at the inner centromeres in prophase 
and metaphase of mitosis, relocalises to the central spindle in anaphase and accumulates at 
the midbody during cytokinesis (Beardmore et al., 2004; Skoufias et al., 2000; Uren et al., 
2000; Wheatley et al., 2001). By interacting with the other members of the CPC, Survivin 
regulates chromosomal alignment, cytokinesis and chromatin-associated spindle assembly 
(Lens et al., 2006). Besides it stabilizes the mitotic spindle by binding to the microtubules 
with its C-terminal α-helix and modulating microtubule dynamics (Giodini et al., 2002; Rosa 
et al., 2006). While Aurora-B is the enzymatic core of the CPC (Ditchfield et al., 2003; Hauf et 
al., 2003), Survivin directs the complex to its correct localisation (Vader et al., 2006), making 
it an important mitotic regulator. Accordingly, it is not surprising, that inhibition of Survivin 
expression result in cell division defects (Chen et al., 2000; Li et al., 1999) and homozygous 
deletion of the Survivin gene leads to early embryonic death (Uren et al., 2000). 
Besides inhibiting apoptosis and its part in the CPC, Survivin was also found being 
accumulated in the nucleus following irradiation and that was linked to an involvement of 
Survivin in DNA double-strand break repair (Figure 5). It has been shown that Survivin 
interacts with DNA-PK, a major repair factor in DNA double-strand break repair, as well as 
MDC1, γH2AX and 53BP1 in colorectal cancer cells and glioblastoma (Capalbo et al., 2010; 
Reichert et al., 2011).  
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Figure 5: Schematic illustration of Survivin’s role in radiation response. In the cytoplasm Survivin 
interacts with HBXIP or other members of the IAP family such as XIAP to inhibit apoptosis. In the 
nucleus it participates in cell cycle regulation as a part of the CPC. Besides it modulates DNA repair by 
interacting with DNA repair factors. HBXIP: hepatitis B X-interacting protein; XIAP: X-linked IAP; CPC: 
chromosomal passenger complex; DNA-PK: DNA-dependent protein kinase. 
 
In line with the presence of Survivin in different subcellular pools in cytoplasm, mitochondria 
and nucleus, a leucine-rich nuclear export signal (NES) was described. Moreover, an 
interaction of this NES of Survivin with the nuclear export receptor chromosome region 
maintenance protein 1 homolog (Crm1) is involved in the intracellular localisation as well as 
cancer-relevant functions of Survivin (Colnaghi et al., 2006; Knauer et al., 2006; Stauber et 
al., 2006).  
Interference with expression or functions of Survivin as well as other IAPs can affect cellular 
homeostasis leading to cancer or other human diseases. In genome wide studies comparing 
normal and cancer tissues, Survivin has been found to be the fourth top transcript uniformly 
elevated in cancers of colon, lung, breast, brain and melanoma while not or less expressed in 
the corresponding non-cancerous tissues (Velculescu et al., 1999). However, expression of 
Survivin is upregulated by various oncogenic pathways, whereas silencing of the Survivin 
gene is achieved by several tumour suppressor networks (Guha and Altieri, 2009). In non-
cancerous cells, Survivin levels can be kept low due to the activated tumour suppressor 
machinery while the activation of oncogenes is associated with an inactivation of tumour 
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suppression, which is then accompanied by an induction of Survivin expression (Guha and 
Altieri, 2009). 
In non-cancerous cells, Survivin expression is controlled in a cell cycle-dependent manner 
with a peak in mitosis (Li et al., 1998) and a pronounced increase in G2/M phase (Altieri, 
2001; Lens et al., 2006). The regulation also involves CDE/CHR (cell cycle-dependent 
element/cell cycle genes homology region) elements located within the Survivin promotor (Li 
and Altieri, 1999).  
In tumour cells, gene expression of Survivin is additionally mediated by cell cycle-
independent mechanisms (Li et al., 2010; Xia and Altieri, 2006). Such mechanisms are the 
demethylation of CpG islands in the promoter region of Survivin (Hattori et al., 2001) or 
increased promoter activity (Li and Altieri, 1999) by oncologic transcription factors like v-Ha-
ras Harvey rat sarcoma viral oncogene homologue (c-H-Ras) (Sommer et al., 2003), v-myc 
myelocytomatosis viral oncogene homologue (c-Myc) (Fang et al., 2009), wingless-related 
integration site (WNT)/β-catenin/transcription factor 4 (TCF4) (Kim et al., 2003), neurogenic 
locus notch homologue (Notch) (Lee et al., 2008), signal transduction and activator of 
transcription 3 (STAT3) (Gritsko et al., 2006), hypoxia inducible factor 1α (HIF-1α) (Wu et 
al., 2010) and E2F transcription factors (Jiang et al., 2004). Besides, Survivin is a 
downstream target of NF-κB (Kawakami et al., 2005), which can be activated by growth 
factors, e.g. mammalian target of rapamycin (mTOR) and insulin (Vaira et al., 2007). While 
the above mentioned factors result an transcriptional activation, a decrease of Survivin 
transcript level can be mediated by wild type tumour suppressor p53 (Xia and Altieri, 2006), 
wild type adenomatous polyposis coli gene (APC) (Zhang et al., 2001) or phosphatase and 
tensin homologue deleted from chromosome ten (PTEN) (Guha et al., 2009).  
The exact mechanisms of the repression or up-regulation of Survivin transcription are not yet 
fully understood. For p53 it is assumed that it is binding directly to the promoter region of 
Survivin (Hoffman et al., 2002) and that chromatin modifications within the Survivin 
promoter (Mirza et al., 2002) and epigenetic modifications by DNA cytosine 
methyltransferase 1 (Esteve et al., 2005) lead to repressed Survivin transcription by p53. In 
case of PTEN, repression of Survivin transcription is caused by occupation of the promoter by 
the transcription factors forkhead box O1 (FOXO1) and FOXO3a (Guha et al., 2009). Another 
Survivin promoter binding protein which represses Survivin transcription by epigenetic 
chromatin modifications is histone deacetylase silent mating type information regulation 2 
homologue 2 (SIRT1). SIRT1 is transcribed via Breast cancer type 1 susceptibility protein 
(BRCA1) (Wang et al., 2008). 
In addition to wild type Survivin mRNA that is predominantly present, there are at least four 
alternative splicing variants of Survivin mRNA (Badran et al., 2004; Caldas et al., 2005; 
Mahotka et al., 1999). These splicing variants differ in their cellular localisation as well as in 
their function in apoptosis regulation (Krieg et al., 2002; Mahotka et al., 2002). 
But regulation of Survivin is not restricted to a transcriptional level. Post-transcriptional 
regulations of Survivin can be ubiquitylation, de-ubiquitylation (Vong et al., 2005; Zhao et al., 
2000) and phosphorylation. There are three known phosphorylation sites in Survivin that are 
involved in different functions and phosphorylated by different kinases: Ser20 (protein kinase 
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A, PKA and polo-like kinase 1, Plk1), Thr34 (cyclin dependent kinase 1, CDK1) and Thr117 
(aurora kinase B) (Colnaghi and Wheatley, 2010; Dohi et al., 2007; O'Connor et al., 2002; 
Wheatley et al., 2007). These post-transcriptional modifications have been implicated in 
protein trafficking through different cellular compartments as well as protein stabilization. 
Binding to the heat shock protein (Hsp) 90 chaperone stabilizes Survivin and prevents it from 
ubiquitin-proteasomal degradation (Fortugno et al., 2003; Zhao et al., 2000).  
 
2.5.2. Survivin as a molecular target in oncology 
Survivin expression has been shown to be low in most terminally differentiated tissues 
(Altieri, 2003b). Nonetheless, Survivin expression was found in endothelial cells, CD34 
positive hematopoietic progenitor cells, basal keratinocyte stem cells and kidney tubuli cells 
(Fukuda and Pelus, 2006; Lechler et al., 2007). However, in most solid and liquid human 
tumours Survivin is highly expressed (Altieri, 2003b; Miura et al., 2011). These elevated 
levels of Survivin expression in tumours were associated with more aggressive 
clinicopathologic features, an increased risk of tumour recurrences and shortened overall 
survival of the patients in many different tumour entities (Altieri, 2003b; Capalbo et al., 2007; 
Mita et al., 2008; Rodel et al., 2012; Sprenger et al., 2011). Due to the different expression in 
normal tissue and cancer cells as well as the involvement in apoptosis inhibition and 
maintaining cancer cell viability, Survivin was supposed to be a promising target for 
molecular cancer therapy (Mita et al., 2008; Pennati et al., 2008). According to this, a variety 
of Survivin-targeting strategies have been developed including mRNA antagonization with 
antisense oligonucleotides, siRNAs, small molecule inhibitors or Survivin-based 
immunotherapy (Mita et al., 2008).  
A multitude of preclinical studies performed in different cancer cell lines could show that 
targeting of Survivin resulted in inhibition of tumour cell proliferation and increased 
apoptosis along with increased sensitivity to TNF-related apoptosis-inducing ligand (TRAIL), 
tumour necrosis factor-α (TNF-α) and chemotherapeutic drugs in cell culture and xenograft 
models (Kelly et al., 2011; Miura et al., 2011). Survivin is further known to be a radio-
resistance factor, leading to a radiation sensitization effect on tumour cells upon Survivin 
down-regulation (Asanuma et al., 2000; Chakravarti et al., 2004; Rodel et al., 2003). A 
reduced clonogenic survival in vitro in different tumour entities as well as tumour growth 
retardation in xenograft models were found after Survivin depletion combined with ionizing 
radiation (Rodel et al., 2011). The complex mechanisms behind these findings far exceed a 
mere radiation-induced apoptosis (Rodel et al., 2011). Additionally, inability to repair 
irradiation-induced DNA damage after Survivin depletion can decrease tumour cell survival 
(Chakravarti et al., 2004). Besides, Survivin-specific siRNA, a small molecule inhibitor of 
Survivin expression (YM155) or antisense oligonucleotides showed a decreased DNA repair 
(Iwasa et al., 2008; Rodel et al., 2008; Rodel et al., 2005). 
In addition to that, several phase I and II clinical trials targeting Survivin were performed, 
applying the small molecule inhibitor YM155 (Astellas Pharma Inc., Tokio, Japan), a second 
generation 2’-O-methoxy-methyl modified antisense oligonucleotide (LY2181308/Gataparsen, 
Eli Lilly and Company, Indianapolis, IN, USA) or immunotherapeutic approaches (Rodel et al., 
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2012). These immunotherapeutic approaches suppose that Survivin might be recognized as a 
“non-self” protein in cancer patients leading to an immune response against it (Andersen and 
Thor, 2002). Such an anti-Survivin T-cell reactivity has been detected in patients suffering 
from a variety of tumour entities (Schmidt et al., 2003).  
 
2.6. Aim of the thesis 
As reported before, besides its role in the regulation of apoptosis and cell cycle progression, 
Survivin is reported to be involved in DNA double-strand break repair most likely by its 
interaction with DNA repair factors such as the catalytic subunit of DNA-dependent protein 
kinase (DNA-PKcs). The aim of the thesis was to gain further insight on the molecular 
mechanisms facilitating a Survivin-mediated regulation of DNA repair by further 
characterising the interrelationship between Survivin and DNA-PKcs, a major enzyme in the 
non-homologous end-joining (NHEJ) DNA double-strand break repair pathway.  
For this purpose the interrelationship of Survivin and DNA-PKcs was analysed by 
immunoprecipitation, GST pulldown assay, NanoLuc Binary Technology (NanoBiT®) 
complementation assay and flow cytometry-based Förster resonance energy transfer (FRET) 
assay. Functional properties were analysed by autophosphorylation of serine 2056 of DNA-
PKcs and kinase assays. 
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3. Materials and Methods 
 
3.1. Materials 
 
3.1.1. Appliances/Instruments 
Appliance/Instrument Model/Description Company 
Agarose gel electrophoresis 
chamber 
 peQLab Biotechnologie, 
Erlangen 
Centrifuges Mini Spin 
UNIVERSAL 329R 
MEGA STAR 1.6R 
Eppendorf AG, Hamburg 
Hettich, Tuttlingen 
VWR, Darmstadt 
Electrophoresis chamber for 
SDS gels + accessories 
Mini-PROTEAN® Tetra 
Vertical Electrophoresis Cell 
Bio-Rad, Munich 
ELISA reader TECAN infinite M200 pro TECAN, Männedorf, 
Switzerland 
Flow cytometer CytoFLEX S Beckman Coulter, Krefeld  
Freezing container Mr. Frosty™ Thermo Fisher Scientific, 
Dreieich 
Gel electrophoresis power 
supply 
Power Pack P25 T Biometra, Göttingen 
Heat sealer Futura Junior Audion, Weesp, the 
Netherlands 
Hotplate/stirrer  VWR, Darmstadt 
Imaging System Odyssey® Fc Imaging System LI-COR, Lincoln, NE, USA 
Incubator HERA cell 240 + 240i Thermo Fisher Scientific, 
Dreieich 
Laminar flow hood HERA safe Thermo Fisher Scientific, 
Dreieich 
Linear accelerator Synergy Elekta, Crawley, UK 
Magnet for Dynabeads DynaMag™-2 Magnet Thermo Fisher Scientific, 
Dreieich 
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Microscopes AxioVert A1 
AxioManager Z1 with Axio 
Vision Imager Software 
4.6.2. and AxioCam MRc 
Zeiss, Jena 
Zeiss, Jena 
pH meter pH Meter 765 Calimatic Knick, Berlin 
Photometer Bio Photometer Eppendorf, Hamburg 
Real time PCR Step One Plus Applied Biosystems, 
Darmstadt 
Scales CP324S 
PRACTUM612-1S 
Sartorius, Göttingen 
 
Semi-dry transfer system Trans-Blot® Turbo™ 
Transfer System 
Bio-Rad, Munich 
Shakers IKA® shaker MTS 4 
IKA® KS 260 basic 
IKA® LOOPSTER digital 
Mixer HC 
ES-20 
IKA Labortechnik, Staufen 
IKA Labortechnik, Staufen 
IKA Labortechnik, Staufen 
STARLAB, Hamburg 
BioSan, Riga, Latvia 
Shaker for bacteria MaxQ 4450 Thermo Fisher Scientific, 
Dreieich 
Thermocycler Primus 96 advanced PEQLab Biotechnologie, 
Erlangen 
Ultrasonic bath Bandelin Sonorex RK 31 BANDELIN electronic, Berlin 
Vortex-Genie 2  Scientific Industries, 
Bohemia, NY, USA 
Water bath Typ W/B 5 Gesellschaft für 
Labortechnik, Burgwedel 
 
 
3.1.2. Consumables 
Description Company 
15 ml tubes Greiner Bio-One, Frickenhausen 
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50 ml tubes Greiner Bio-One, Frickenhausen 
60 mm cell culture dishes Sarstedt, Nümbrecht 
100 mm cell culture dishes Sarstedt, Nümbrecht 
96-well micro-plates Greiner Bio-One, Frickenhausen 
Cell scraper M TPP, Trasadingen, Switzerland 
CELLSTAR® 6-well cell culture plates Greiner Bio-One, Frickenhausen 
CELLSTAR® 12-well cell culture plates Greiner Bio-One, Frickenhausen 
CELLSTAR® 24-well cell culture plates Greiner Bio-One, Frickenhausen 
CELLSTAR® 96-well cell culture plates Greiner Bio-One, Frickenhausen 
CELLSTAR® 96-well cell culture plates, 
white polystyrene wells flat bottom 
Greiner Bio-One, Frickenhausen 
CELLSTAR® Filter Top cell culture flasks Greiner Bio-One, Frickenhausen 
C-Chip Disposable Hematocytometer, Digital 
Bio 
NanoEnTek, Seoul, South Korea 
Cover foil, Easy seal (80x140 mm) Greiner Bio-One, Frickenhausen 
CryoPure Tube 1.8 ml Sarstedt, Nümbrecht 
Culture slides 8 chambers BD Falcon, Erembodegem, Belgium 
FACS tubes, flow cytometry Sarstedt, Nümbrecht 
Filter paper Whatman, Kent, UK 
Glass beakers Schott, Mainz 
Insulin syringes B. Braun, Melsungen 
Microscope cover glasses (24x60 mm) Marienfeld, Lauda-Königshofen 
Microscopic slides Thermo Fisher Scientific, Dreieich 
Mini-PROTEAN® TGX™ Precast Gels Bio-Rad, Munich 
Petri dish (sterile, 92x16 mm) 
Sarstedt, Nümbrecht 
Pipette-tips, TipOne®, graduated, 
blue/yellow/white  
Starlab, Hamburg 
Pipette-tips, TipOne®, graduated, filter tips  Starlab, Hamburg 
Polystyrene Round-Bottom tubes (14 ml) Becton Dickinson, Heidelberg 
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Reaction tubes (0.5 ml) Eppendorf, Hamburg 
Reaction tubes (1.5 ml) Sarstedt, Nümbrecht 
Reaction tubes (2.0 ml) Sarstedt, Nümbrecht 
LoBind reaction tubes (1.5 ml) Eppendorf, Hamburg 
Trans-Blot® Turbo™ Mini Nitrocellulose 
Transfer Packs 
Bio-Rad, Munich 
 
 
3.1.3. Chemicals and media 
Description Company 
3-(N-morpholino)propanesulfonic acid 
(MOPS) 
Carl Roth, Karlsruhe 
4′.6-Diamidin-2-phenylindol (DAPI) Molecular Probes, Eugen, OR, USA 
Agarose NEEO Ultra-Quality Carl Roth, Karlsruhe 
Acetic acid J. T. Baker (Fisher Scientific), Schwerte 
Albumin Fraction V (pH 7) AppliChem, Darmstadt 
Ammonium peroxodisulfate (APS) Carl Roth, Karlsruhe 
Ampicillin Carl Roth, Karlsruhe 
32P ATP (250 µCi) PerkinElmer, Waltham, MA, USA 
Benzonase® Nuclease Sigma-Aldrich, St. Louis, MO, USA 
Bromophenol blue AppliChem, Darmstadt 
No-Weigh™ BS3 Thermo Fisher Scientific, Dreieich 
Bovine Serum Albumin (BSA) AppliChem, Darmstadt 
Calcium chloride AppliChem, Darmstadt 
CelLytic™ B Cell Lysis Reagent (2x) Sigma-Aldrich, St. Louis, MO, USA 
Coomassie Brilliant Blue G-250 Thermo Fisher Scientific, Dreieich 
CytoFLEX Sheath Fluid Beckman Coulter, Brea, CA, USA 
Distilled water Thermo Fisher Scientific, Dreieich 
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Deoxynucleotides (dNTP) (10 mM) Thermo Fisher Scientific, Dreieich 
Dichloroacetic acid (DCA) AppliChem, Darmstadt 
Dulbecco’s Phosphate Buffered Saline (PBS) Thermo Fisher Scientific, Dreieich 
Dulbecco’s Modified Eagle Medium (DMEM) Thermo Fisher Scientific, Dreieich 
Dithiothreitol (DTT) Sigma-Aldrich, St. Louis, MO, USA 
Dimethyl sulfoxide (DMSO) AppliChem, Darmstadt 
Dynabeads™ Protein G Thermo Fisher Scientific, Dreieich 
Effectene transfection reagent QIAGEN, Hilden 
Ethanol Sigma-Aldrich, St. Louis, MO, USA 
Ethylenediaminetetraacetic acid (EDTA) AppliChem, Darmstadt 
Ethidium bromide (EtBr) Carl Roth, Karlsruhe 
Fetal bovine serum (FBS Thermo Fisher Scientific, Dreieich 
Geneticin (G418) AppliChem, Darmstadt 
Glycerine Carl Roth, Karlsruhe 
Glutathione Sepharose™ 4 Fast Flow GE Healthcare, Little Chalfont, UK 
Glycine AppliChem, Darmstadt 
Halt™ Protease Inhibitor Single-Use Cocktail Thermo Fisher Scientific, Dreieich 
Hydrogen chloride (HCl) AppliChem, Darmstadt 
IPTG BioChemica AppliChem, Darmstadt 
Isopropanol Sigma-Aldrich, St. Louis, MO, USA 
K2 transfection system Biontex, Munich 
Kanamycin Carl Roth, Karlsruhe 
LB medium Carl Roth, Karlsruhe 
LB agar Carl Roth, Karlsruhe 
Lysozyme Sigma-Aldrich, St. Louis, MO, USA 
Methanol Sigma-Aldrich, St. Louis, MO, USA 
Methylene blue C.I. 52015 AppliChem, Darmstadt 
Milk powder Carl Roth, Karlsruhe 
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Nonidet P-40 AppliChem, Darmstadt 
Non-reducing Lane Marker, Sample Buffer Thermo Fisher Scientific, Dreieich 
Opti-MEM I Thermo Fisher Scientific, Dreieich 
Penicillin 10.000 Units, Streptomycin 
10 mg/ml 
Sigma-Aldrich, St. Louis, MO, USA 
PerfeCTa® SYBR® Green SuperMix, ROX Quantabio, Beverly, MA, USA 
peqGREEN  DNA/RNA Dye PEQLab Biotechnologie, Erlangen 
Pierce® ECL, Western Blotting Substrate Thermo Fisher Scientific, Dreieich 
Ponceau S AppliChem, Darmstadt 
Propidium iodide Thermo Fisher Scientific, Dreieich 
Ribonuclease A (RNase A; 100 mg/ml) QIAGEN, Hilden 
RNAse/DNase-free water Thermo Fisher Scientific, Dreieich 
Roti-Fect PLUS Carl Roth, Karlsruhe 
Rotiphoresis gel 30 Carl Roth, Karlsruhe 
Roswell Park Memorial Institute (RPMI)-
1640 medium 
Thermo Fisher Scientific, Dreieich 
Rubidium chloride Sigma-Aldrich, St. Louis, MO, USA 
Silicon for cloning cylinders Momentive performance materials, Albany, 
NY, USA 
Sodium hydroxide (NaOH) Sigma-Aldrich, St. Louis, MO, USA 
Sodium chloride (NaCl) Sigma-Aldrich, St. Louis, MO, USA 
Sodium dodecylsulfate (SDS) pellets Carl Roth, Karlsruhe 
Sodium dodecylsulfate (SDS) 20% solution AppliChem, Darmstadt 
Sodium fluoride Sigma-Aldrich, St. Louis, MO, USA 
Sodium orthovanadate Sigma-Aldrich, St. Louis, MO, USA 
Tetramethylethylenediamin (TEMED) Carl Roth, Karlsruhe 
Trichloroacetic acid (TCA) AppliChem, Darmstadt 
Trypan Blue Stain 0.4% Thermo Fisher Scientific, Dreieich 
Trypsin/Ethylene diamine tetraacetic acid Thermo Fisher Scientific, Dreieich 
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(EDTA, 0.25%) 
Tween® 20 AppliChem, Darmstadt 
Tris hydroxymethyl aminomethane (Tris) Carl Roth, Karlsruhe 
Triton X-100 AppliChem, Darmstadt 
Vectashield® Mounting Medium Vector, Burlingame, CA, USA 
WesternSure® PREMIUM Chemiluminescent 
Substrate 
LI-COR, Lincoln, NE, USA 
 
 
3.1.4. Solutions and buffers 
 
Immunofluorescence 
DAPI staining solution   600 ng/ml in PBS 
Fixing/permeabilisation solution  3.7% Formaldehyde/0.25% Triton X-100 in PBS 
Blocking/antibody dilution solution  5% BSA in PBS 
 
SDS-PAGE and western blotting 
Radio-immunoprecipitation assay (RIPA) buffer (10x) 
 1.752 g NaCl 
 2 ml  NP-40 
 1 g  DCA 
 1 ml  SDS (20% solution) 
 6.67 ml 1.5 M Tris, pH 8.0 
 adjust volume to 20 ml distilled water 
 
IP lysis buffer (1x) 
 2 ml  1 M Tris, pH 8.2 
 15 ml  1 M NaCl 
 1 ml  Triton X-100 
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 adjust volume to 100 ml distilled water 
 
1 M Tris HCl, pH 8.8 
 121.2 g Tris 
 adjust volume to 1 l with distilled water 
 adjust pH 8.8 with HCl 
 
1 M Tris HCl, pH 6.8 
 60.6 g  Tris 
 adjust volume to 500 ml with distilled water 
 adjust pH 6.8 with HCl 
 
SDS electrophoresis buffer (10x) 
 30.3 g  Tris 
 144 g  Glycine 
 10 g  SDS pellets 
 adjust volume to 1 l with distilled water 
 
Tris-buffered saline (TBS, 10x), pH 7.5 
 87.7 g  NaCl 
 12.1 g  Tris 
 adjust volume to 1 l with distilled water 
 adjust pH 7.5 with HCl 
 
TBS-Tween 20 (TBS-T) 
 100 ml  TBS (10x) 
 1 ml  Tween 20 
 adjust volume to 1 l with distilled water 
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Antibody diluent 
 0.5 g  BSA 
 adjust volume to 10 ml with TBS-T 
 
Milk powder solution 
 0.5 g  milk powder 
 adjust volume to 10 ml with TBS-T 
 
Ponceau solution 
 0.5 g  Ponceau S 
 37.5 ml TCA  
 adjust volume to 250 ml with distilled water 
 
Reducing electrophoresis buffer (6x) 
 25 ml  Glycerol 
 4.63 g  DTT 
 5.14 g  SDS pellet 
 17.5 ml 1 M Tris/HCl, pH 6.8 
 0.25 mg Bromophenol blue 
 adjust volume to 50 ml with distilled water 
 
Coomassie staining solution 
 2.5 g  Coomassie Brilliant Blue G-250 
 454 ml  Methanol 
 92 ml  Acetic acid 
 adjust volume to 1 l with distilled water 
mix 30 min on magnetic stirrer then filter with pleated filter 
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Coomassie destaining solution 
 400 ml  Methanol 
 100 ml  Acetic acid 
 adjust volume to 1 l with distilled water 
 
Agarose gel electrophoresis 
DNA loading dye Blue Run (5x) 
 1.25 ml  1 M Tris/HCl, pH 7.0 
 15 ml  0.5 M EDTA 
 25 mg  Bromophenol blue 
 12.5 ml  Glycerol 
 adjust volume to 50 ml with distilled water 
 
Tris acetate EDTA (TAE) buffer (50x) 
 242 g  Tris (in 500 ml distilled water) 
 100 ml  0.5 M Na2EDTA, pH 8.0 
 57.1 ml glacial acetic acid 
 adjust volume to 1 l with distilled water 
  
Growth media for bacteria 
LB medium 
 20 g  LB medium 
 adjust volume to 1 l with distilled water 
 
LB agar plates 
 35 g  LB agar 
 adjust volume to 1 l with distilled water 
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Preparation of competent Escherichia coli (E. coli) 
MOPS I solution 
 10 ml  0.5 M MOPS 
 5 ml  0.1 M RbCl 
 adjust volume to 50 ml with distilled water 
 adjust pH 7.0 with 1 M NaOH 
 
MOPS II solution 
 10 ml  0.5 M MOPS 
 5 ml  0.1 M RbCl 
 5 ml  0.7 M CaCl2 
 adjust volume to 50 ml with distilled water 
 adjust pH 6.5 with 1 M NaOH 
 
3.1.5. Antibodies 
Table 1: Characteristics of primary antibodies used for western immunoblotting, immunoprecipitation 
and immunofluorescence staining. 
Target Host Type 
Stock 
solution 
[µg/ml] 
Dilution 
Molecular 
weight 
[kDa] 
Company 
Catalogue 
number 
Anti-β-
Actin 
mouse IgG 1000 1:10 000 42 
Sigma-
Aldrich 
A5441 
Anti-
Lamin B1 
mouse 
IgG1-
Kappa 
200 1:200 68 MBL 
JM-3046-
100 
Anti-
Calnexin 
mouse IgG 250 1:500 90 
BD 
Biosciences 
610524 
Anti-
Survivin 
rabbit IgG 200 1:750 16.5 
R&D 
Systems 
AF886 
Anti-
phospho-
H2AX 
(Ser139) 
 
mouse IgG1 1000 1:1000 17 Millipore 05-636 
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Anti-
53BP1 
rabbit IgG 1 1:1000 250 
Novus 
Biologicals 
NB100-304 
Anti-GFP mouse IgG 2000 1:1000 27 Abcam ab1218 
Anti-GFP rabbit IgG 2000 1:1000 27 Abcam ab290 
Anti-GST mouse IgG 200 1:8000 26 Santa Cruz sc-138 
Anti-DNA-
PKcs 
mouse IgG 200 1:500 470 Thermo MS-370-P0 
Anti-DNA-
PKcs 
mouse IgG 200 1:500 470 Abcam ab44815 
Anti-
pDNA-
PKcs 
S2056 
rabbit IgG 600 1:500 470 Abcam ab18192 
Isotype 
control 
rabbit IgG 2500 1:100 - 
Cell 
Signaling 
3900 
Isotype 
control 
mouse IgG 2500 1:100 - 
Cell 
Signaling 
5415 
 
 
Table 2: Characteristics of secondary antibodies used for immunofluorescence staining. 
Target Host Type Dilution Label Company Catalogue number 
Anti-
rabbit  
goat IgG 1:500 
Alexa 
FluorR 488 
Life 
technologies 
A11034 
Anti-
mouse  
goat IgG 1:500 
Alexa 
FluorR 594 
Life 
technologies  
A11032 
 
 
Table 3: Characteristics of secondary antibodies used for western immunoblotting. 
Coupled enzyme Specificity Host Type Dilution Company 
Catalogue 
number 
Horse radish 
peroxidase 
rabbit goat IgG 1:1000 
Southern 
Biotech 
4050-05 
Horse radish 
peroxidase 
mouse goat IgG 1:1000 
Southern 
Biotech 
1030-05 
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3.1.6. Expression plasmids 
 
pEYFP-C1 
In addition to pEYFP-C1, pECFP-C1 was used, too. It is based on the exact same plasmid 
backbone, the only difference is the included fluorescence gene. 
 
Figure 6: Plasmid map of pEYFP-C1 (Clonetech, Mountain View, CA, USA). The map of the 4731 bp long 
plasmid shows characteristic vector elements like promotors, origins of replication (ori), a resistance 
gene against Neomycin/Kanamycin as well as the EYFP reporter gene (yellow) followed by the multiple 
cloning site (MCS) including restriction sites. The plasmid map was created with SnapGene (GSL Biotech 
LLC, Chicago, IL, USA). 
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pEYFP-N1 
In addition to pEYFP-N1, pECFP-N1 and pEGFP-N1 were used, too. They are based on the 
exact same plasmid backbone, the only difference is the included fluorescence gene. 
 
 
Figure 7: Plasmid map of pEYFP-N1 (Clonetech, Mountain View, CA, USA). The map of the 4733 bp long 
plasmid shows characteristic vector elements like promotors, origins of replication (ori), a resistance 
gene against Neomycin/Kanamycin as well as the multiple cloning site (MCS) including restriction sites 
followed by the EYFP reporter gene (yellow). The plasmid map was created with SnapGene (GSL 
Biotech LLC, Chicago, IL, USA). 
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pH3FE 
This plasmid was kindly provided by Dr. Yves Matthess, AG Prof. Strebhardt, Goethe-
University Frankfurt. It is derived of the pcDNA3.1/Hygro(+) plasmid (Invitrogen, Carlsbad, 
CA, USA) where a FLAG tag was inserted into its NheI/HindIII sites. Also the EcoRI site in this 
plasmid was mutated.  
 
Figure 8: Plasmid map of pH3FE. This 5653 bp long plasmid is derived from the pcDNA3.1/Hygro(+) 
plasmid where a FLAG tag was inserted into its NheI/HindIII sites and the EcoRI site was mutated. The 
map shows characteristic vector elements like promotors, origins of replication (ori), a resistance gene 
against Ampicillin as well as the FLAG reporter gene (blue) followed by the multiple cloning site (MCS) 
including restriction sites. The plasmid map was created with SnapGene (GSL Biotech LLC, Chicago, IL, 
USA). 
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pGEX-5X-3 
The pGEX-5X-3 plasmid (GE Healthcare, Little Chalfont, UK) was kindly provided by Dr. Yves 
Matthess, group of Prof. Strebhardt, Goethe-University Frankfurt. He additionally included a 
KpnI restriction site to the multiple cloning site (MCS) of the plasmid. 
 
Figure 9: Plasmid map of pGEX-5X-3 (GE Healthcare, Little Chalfont, UK). The map of the 4974 bp long 
plasmid shows characteristic vector elements like promotors, origins of replication (ori), a resistance 
gene against Ampicillin as well as the GST reporter gene (red) followed by the multiple cloning site 
(MCS) including restriction sites. A KpnI restriction site was additionally added to the MCS. The plasmid 
map was created with SnapGene (GSL Biotech LLC, Chicago, IL, USA). 
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3.1.7. Specific small interfering RNA 
 
Survivin specific small interfering RNA (siRNA) 
Negative control siRNA   QIAGEN, Hilden 
BIRC5 Survivin 3 siRNA (#s1458)  Ambion, Austin, TX, USA 
Sequence (5’ à 3’) Sense:  GCAGGUUCCUUAUCUGUCAtt  
    Antisense: UGACAGAUAAGGAACCUGCag  
 
3.1.8. Commercial kits 
Description Company 
Homologous Recombination Assay Kit Norgen Biotek, Thorold, Ontario, Canada 
Micro BCA™ Protein Assay Kit Thermo Fisher Scientific, Dreieich 
NanoBiT Complementation Assay Promega, Madison, WI, USA 
Nuclear Complex Co-IP Kit Active Motif, La Hulpe, Belgium 
NucleoBond® Xtra Midi Plus EF Macherey-Nagel, Dueren 
NucleoSpin® Plasmid Kit Macherey-Nagel, Dueren 
NucleoSpin® Gel and PCR Clean-Up Kit Macherey-Nagel, Dueren 
NucleoSpin® RNA Macherey-Nagel, Dueren 
NucleoSpin® Tissue Macherey-Nagel, Dueren 
PCR Mycoplasma Test Kit AppliChem, Darmstadt 
SignaTECT® DNA-Dependent Protein Kinase 
Assay 
Promega, Madison, WI, USA 
 
 
3.1.9. Enzymes and respective buffers 
Description Company 
PfuUltra High-Fidelity DNA Polymerase Strategene, La Jolla, CA, USA 
PfuUltra HF Reaction Buffer (10x) Strategene, La Jolla, CA, USA 
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T4 DNA Ligase New England Biolabs, Frankfurt 
T4 DNA Ligase Buffer (10x) New England Biolabs, Frankfurt 
Taq DNA Polymerase Sigma-Aldrich, St. Louis, MO, USA 
10x PCR Reaction Buffer Sigma-Aldrich, St. Louis, MO, USA 
M-MLV Reverse Transcriptase Promega, Madison, WI, USA 
M-MLV Reaction Buffer (5x) Promega, Madison, WI, USA 
ApaLI, 10 U/µl New England Biolabs, Frankfurt 
EcoRI, 20 U/µl New England Biolabs, Frankfurt 
KpnI, 10 U/µl New England Biolabs, Frankfurt 
NheI, 10 U/µl New England Biolabs, Frankfurt 
SacI, 20 U/µl New England Biolabs, Frankfurt 
NEB Buffer 10x New England Biolabs, Frankfurt 
 
 
3.1.10. Electrophoresis markers 
Description Company 
ProSieve QuadColor Protein Marker Lonza, Cologne 
GelPilot 1kb Plus Ladder QIAGEN, Hilden 
 
 
3.1.11. Oligonucleotides 
The melting temperature (Tm) of the oligonucleotides was calculated according to the formula 
from Nelson and Brutlag (1979): Tm = 4 °C x (G + C) + 2 °C x (A + T). The oligonucleotides 
were ordered from Eurofins Genomics (Ebersberg, Germany). Concentration of the 
oligonucleotides was first adjusted to 100 pmol/µl and then diluted to a working 
concentration of 10 µM. Oligonucleotides were stored at -20 °C. 
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Primers for cloning of GST-PI3K 
Table 4: Primers for cloning of the GST-PI3K construct. The protein of interest sequence is labelled in 
cyan, stop codon in red and restriction sites in yellow. fw = forward, rv = reverse. 
Primer Sequence 5’ à  3’ Restriction 
site 
PI3K_KpnI_fw ACTGGTACCGAACACCCTTTCCTGGTGA KpnI 
PI3K_EcoRI_rv ACTGAATTCTTAATTTTTCCAATCAAAGGAGGG EcoRI 
 
 
Primers for cloning of the NanoBiT® Complementation Assay constructs 
Table 5: Primers for cloning of the NanoBiT® Complementation Assay constructs. The protein of 
interest sequences are labelled in cyan, start/stop codons in red, restriction sites in yellow and kozak 
sequence in grey. fw = forward, rv = reverse. 
Primer Sequence 5’ à  3’ Restriction 
site 
1.1-C-PI3K-fw ATCTAGCTAGCGGCGGCATGGAACACCCTTTCCTGGTGAAG NheI 
1.1-C-PI3K-rv ACTGGGAGCTCCATTTTTCCAATCAAAGGAGGGC SacI 
1.1-N-PI3K-fw ACTGCGAGCTCAGGAACACCCTTTCCTGGTGAAG SacI 
1.1-N-PI3K-rv TACTAGCTAGCTTAATTTTTCCAATCAAAGGAGGGC NheI 
1.1-C-Surv-fw ATCTAGCTAGCGGCGGCATGGGTGCCCCGACGTTGC NheI 
1.1-C-Surv-rv ACTGGGAGCTCCATCCATGGCAGCCAGCTGC SacI 
1.1-N-Surv-fw ACTGCGAGCTCAGGGTGCCCCGACGTTGCCC SacI 
1.1-N-Surv-rv TACTAGCTAGCTCAATCCATGGCAGCCAGCTG NheI 
 
 
Primers for cloning of the Förster resonance energy transfer (FRET) constructs 
Table 6: Primers for cloning of the FRET constructs. The protein of interest sequences are labelled in 
cyan, start/stop codons in red, restriction sites in yellow and kozak sequence in grey. fw = forward, rv = 
reverse. 
Primer Sequence 5’ à  3’ Restriction 
site 
pECFP-C1-PI3K_fw CGGAATTCTGAACACCCTTTCCTGGTGAAG EcoRI 
pECFP-C1-PI3K_rev GGGGTACCTTAATTTTTCCAATCAAAGGAGGG KpnI 
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pECFP-N1-PI3K_fw 
 
CGGAATTCGGCGGCATGGAACACCCTTTCCTGGTGAAG EcoRI 
pECFP-N1-PI3K_rev GGGGTACCGTATTTTTCCAATCAAAGGAGGGC KpnI 
pECFP/YFP-C1-
HEAT1_fw 
CGGAATTCTGCGGGCTCCGGAGCCGGT 
EcoRI 
pECFP/YFP-C1-
HEAT1_rv 
GGGGTACCTTAGTTTATAACCTTGCACGG 
KpnI 
pECFP/YFP-N1-
HEAT1_fw 
CGGAATTCGGCGGCATGGCGGGCTCCGGAGCCGGT 
EcoRI 
pECFP/YFP-N1-
HEAT1_rv 
GGGGTACCGTGTTTATAACCTTGCACGGTCC 
KpnI 
pECFP/YFP-C1-
FATC_fw 
CGGAATTCTCTGAAAAAAGGAGGGTCATGG 
EcoRI 
pECFP/YFP-C1-FATC_rv GGGGTACCTTACATCCAGGGCTCCCAT KpnI 
pECFP/YFP-N1-
FATC_fw 
CGGAATTCGGCGGCATGCTGAAAAAAGGAGGGTCATGG 
EcoRI 
pECFP/YFP-N1-FATC_rv GGGGTACCGTCATCCAGGGCTCCCATCCT KpnI 
pECFP-C1-Survivin_fw CGGAATTCTGGTGCCCCGACGTTGCCC EcoRI 
pECFP-C1-Survivin_rev GGGGTACCTCAATCCATGGCAGCCAGCTGC KpnI 
pECFP-N1-Survivin_fw CGGAATTCGGCGGCATGGGTGCCCC EcoRI 
pECFP-N1-Survivin_rev GGGGTACCGTATCCATGGCAGCCAGCTGCT KpnI 
 
 
Primers for sequencing 
Table 7: Primers used for sequencing of the cloned constructs. fw = forward, rv = reverse. 
Primer Sequence 5’ à  3’ Application 
pGex for ATAGCATGGCCTTTGCAGG GST-PI3K construct 
pGex rev GAGCTGCATGTGTCAGAGG GST-PI3K construct 
Forward TK CACCGAGCGACCCTGCAGC NanoBiT constructs 
pBiT1.1-C TCATCCACAGGGTACACCAC NanoBiT constructs 
pBiT2.1-C + 2.1-N CTGCATTCTAGTTGTGGTTTGTCC NanoBiT constructs 
pBiT1.1-N TCACTGCATTCTAGTTGTGG NanoBiT constructs 
 Materials and Methods 39 
pEGFPC1for GATCACTCTCGGCATGGAC FRET constructs 
pEGFPC1rev CATTTTATGTTTCAGGTTCAGGG FRET constructs 
CMVfor CGCAAATGGGCGGTAGGCGTG FRET constructs 
pEGFPN1rev GTCCAGCTCGACCAGGATG FRET constructs 
 
 
3.1.12. Cells 
 
Bacteria 
Escherichia coli (E. coli) DH5α (Promega, Madison, WI, USA) were used for all cloning 
procedures. For the expression of GST fusion proteins, the IPTG inducible strain E. coli BL21 
One Shot™ BL21 Star™ (DE3) (Thermo Fisher Scientific, Dreieich) was used.  
 
Human cell lines 
HEK-293T: The HEK-293T cell line is a highly transfectable derivate of human embryonic 
kidney 293 cells. They contain the SV40 T-antigen and are competent to 
replicate vectors carrying the SV40 region of replication. Originally, 293T cells 
were referred to as 293tsA1609neo. The cells were cultured in Dulbecco’s 
Minimal Essential Medium (DMEM) supplemented with 10% FBS, 50 U/ml 
penicillin and 50 µg/ml streptomycin at 37 °C in a humidified atmosphere 
containing 5% CO2. 
 
A2780: The A2780 cell line was established from human ovarian endometroid 
adenocarcinoma tumour tissue of an untreated patient. A2780 cells are p53 
wild type. The cells were cultured in Roswell Park Memorial Institute (RPMI)-
1640 medium supplemented with 10% FBS, 50 U/ml penicillin and 50 µg/ml 
streptomycin at 37 °C in a humidified atmosphere containing 5% CO2. 
 
LN-229: The LN-229 cell line was established from a right frontal parieto-occipital 
glioblastoma in 1979. It has a C/T mutation at codon 98 of p53. The cells were 
cultured in DMEM supplemented with 10% FBS, 50 U/ml penicillin and 
50 µg/ml streptomycin at 37 °C in a humidified atmosphere containing 5% 
CO2. LN-229 cells stably transfected with plasmids encoding different Survivin 
mutants were created within this work. These mutant cell lines were cultivated 
in DMEM supplemented with 10% FBS, 50 U/ml penicillin, 50 µg/ml 
streptomycin and 750 µg/ml G418. 
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OVSAHO: The OVSAHO cell line was established from a human ovarian tumour. Its p53 is 
mutated and BRCA2 homozygously deleted (Domcke et al., 2013). The cells 
were cultured in RPMI-1640 medium supplemented with 10% FBS, 50 U/ml 
penicillin and 50 µg/ml streptomycin at 37 °C in a humidified atmosphere 
containing 5% CO2.  
 
SW480: The SW480 cell line was established from a primary adenocarcinoma of the 
colon by A. Leibovitz in the 1970s. It has two p53 mutations, a G/A mutation 
at codon 273 and a C/T mutation at codon 309. The cells were cultured in 
DMEM supplemented with 10% FBS, 50 U/ml penicillin and 50 µg/ml 
streptomycin at 37 °C in a humidified atmosphere containing 5% CO2. SW480 
cells stably transfected with plasmids encoding different Survivin mutants were 
kindly provided by Dr. Chrysi Petraki. These mutant cell lines were cultivated 
in DMEM supplemented with 10% FBS, 50 U/ml penicillin, 50 µg/ml 
streptomycin and 750 µg/ml G418. 
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3.2. Methods 
 
3.2.1. Cell culture 
The respective cell lines were passaged every 3 to 4 days at a confluency of about 90%. 
Therefore, the cell culture medium was removed, cells were washed with 10 ml PBS and 
detached using 2 ml trypsin/EDTA and incubation for approximately 5 min at 37 °C and 5% 
CO2. The trypsin/EDTA reaction was stopped and the cells resuspended by adding the 
respective cell culture medium. The cell suspension was then diluted 1:4 – 1:12 according to 
the different cell lines and plated on T-75 flasks with 12 ml of the respective medium 
(3.1.12). 
Depending on the experiments, different numbers of cells were seeded. Therefore, they were 
counted in chamber slides (NanoEnTek) following trypsinization. Trypan blue staining was 
used to differentiate between living and dead cells. The number of viable cells was quantified 
according to the manufacturers instructions. 
Cell culture supernatants were regularly checked for contaminations with mycoplasma via a 
PCR-based mycoplasma test kit. 
 
3.2.2. Freezing and thawing of cells 
For freezing, cells were washed with PBS, trypsinized, centrifuged (100 x g, 5 min, room 
temperature (RT)), resuspended in precooled cryomedium (DMEM/RPMI + 20% FBS + 5% 
DMSO) and 1 ml, including 1 x 106 cells, was transferred into each cryotube. Those were then 
stored in a freezing container at -80 °C to allow gentle cooling by 1 °C per hour. The next day, 
the cryotubes were transferred into storage boxes and kept at -80 °C. 
For thawing, cells were transferred into 5 ml of the respective prewarmed medium as fast as 
possible. After centrifugation (100 x g, 5 min, RT) cells were resuspended in 12 ml fresh 
medium and plated on a T-75 flask. 
 
3.2.3. Depletion of endogenous Survivin with siRNA 
Transfection of cells with siRNA using Roti-Fect PLUS is transient and therefore of limited 
duration. The reagent uses the principle of importing siRNA into the cell by the formation of 
DNA lipid complexes. Once in the cell, the siRNA is interacting with the complement mRNA, 
leading to a suppression of the corresponding protein production. For the attenuation of 
endogenous Survivin, siRNA targeting the 3’-untranslated region (UTR) of Survivin mRNA 
was used.  
For transfection with Roti-Fect PLUS, cells were seeded aiming for a confluency of 
approximately 40% at 24 h after plating in 6-wells. Control siRNA and Survivin siRNA were 
diluted in serum-free Opti-MEM to a final concentration of 20 nM and a volume of 125 µl for 
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each well. Roti-Fect PLUS transfection reagent was also diluted in serum-free Opti-MEM (5 µl 
Roti-Fect PLUS + 120 µl Opti-MEM per well). After incubation at RT for 5 min, the diluted 
siRNA was added to the Roti-Fect PLUS dilution and incubated at RT for 20 min. In the 
meantime, cells were washed with PBS once and 1 ml of pre-warmed serum-free Opti-MEM 
was added. Afterwards, the siRNA/Roti-Fect PLUS solution was mixed and 250 µl were added 
dropwise to each well. After incubation for 8 h at 37 °C and 5% CO2, 1.25 ml Opti-MEM/20% 
FBS was added to stop transfection. The transfected cells were then incubated for at least 
another 16 h at 37 °C and 5% CO2 prior to any further experiments.  
 
3.2.4. Transient transfection of DNA plasmids 
For the transient transfection of cells with plasmid DNA, two different transfection reagents 
were used, depending on the further experiments. Both reagents use the principle of the 
uptake of DNA into the cell by the formation of DNA lipid complexes.  
The K2 Transfection System was used for transient transfection of SW480 cells for GST pull-
down assays as well as stable transfection of LN-229 cells with EGFP constructs. Effectene 
transfection reagent was used for protein-protein interaction studies with the NanoBiT® 
complementation assay and Förster resonance energy transfer (FRET) assay, as well as 
homologous recombination assay. In all three experiments, single and double transfections 
with one or two plasmids were performed, though different DNA concentrations were used 
depending on the conducted assay. 
 
3.2.5. Stable transfection  
For the stable transfection of LN-229 cells, the constructs first had to be linearized using 30 µg 
of plasmid DNA, 10 µl 10x NEBuffer, 4 µl ApaLI enzyme (10 U/µl), 1 µl BSA (100x) and 
volumes were adjusted to 100 µl with RNase/DNase-free water in 1.5 ml tubes. After 
incubation at 37 °C overnight, linearization was confirmed via agarose gel electrophoresis and 
subjected to PCR clean-up using the NucleoSpin® Gel and PCR Clean-Up Kit (Macherey-
Nagel) following manufacturer’s instructions. LN-229 cells were then stably transfected with 
pEGFP-N1, Survivin-EGFP or SurvivinΔXIAP-EGFP using the K2 Transfection System. 
Therefore, cells were seeded aiming for a confluency of approximately 80% at 24 h after 
plating in 6-wells. Before transfection, medium was exchanged with 1125 µl fresh medium (+ 
20% FBS + 1% P/S) and 11.25 µl K2 Multiplier was added to each 6-well, followed by an 
incubation for 2 h at 37 °C and 5% CO2. Meanwhile, 4 µg of the linearized plasmid DNA was 
mixed with 67.5 µl serum-free Opti-MEM per transfected 6-well (solution A) and 4.5 µl K2 
transfection reagent was mixed with 67.5 µl serum-free Opti-MEM per transfected 6-well 
(solution B). Both solutions were carefully mixed and solution A was added to solution B 
respectively, followed again by careful mixing. After 20 min incubation at RT and 2 h 
incubation of the cells with K2 Multiplier, 142 µl of the DNA lipid complexes were added to 
the 6-wells and mixed by careful pivoting. Following transfection in 6-well plates and further 
incubation at 37 °C and 5% CO2, cells were transferred to 100 mm petri dishes where colonies 
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were allowed to grow. For selection of transfected cells, the DMEM medium supplemented 
with 10% FBS and 1% P/S was enriched with 750 µg/ml G418.  
Clones were isolated from 100 mm petri dishes when some colonies were large enough to be 
visible by naked eye. Therefore, the dishes were washed with PBS and transferred to a 
fluorescence microscope where fluorescent colonies were selected. The dishes were then 
taken back under the laminar flow hood and silicon-embedded cloning cylinders were 
carefully placed on the selected colonies. Cells within the cloning cylinders were detached 
with 60 µl trypsin/EDTA, incubated for 5 min at 37 °C and 5% CO2, resuspended with 60 µl 
DMEM (+ 10% FBS + 1% P/S) and transferred into 12-well plates (one clone per well) along 
with 1 ml medium (DMEM + 10% FBS + 1% P/S + 750 µg/ml G418). When cells were 
grown to a confluency of approximately 60-80% they were transferred to T-25 flasks and later 
(when 80-100% confluent) harvested for cryostocks. 
EGFP expression of the different stably transfected clones was verified via western blotting as 
well as fluorescence microscopy using an Axiovert 40 CFL microscope after staining the nuclei 
with DAPI. 
 
3.2.6. Irradiation procedure 
For irradiation with X-rays, cells were exposed to single doses from 1 to 4 Gy photons using a 
linear accelerator (Synergy, Elekta, Crawley, UK) with 6 MeV/100 cm focus-surface distance 
and a dose rate of 6 Gy/min. Non-irradiated controls were kept in parallel at ambient 
temperature in the accelerator control room. Medical physics experts of the Department of 
Radiotherapy and Oncology performed regular dosimetry. 
 
3.2.7. Harvesting and lysis of cells 
For cell lysis using radioimmunoprecipitation assay buffer (RIPA), cells were washed once 
with ice-cold PBS and scraped in RIPA buffer on ice at the respective time points after 
irradiation. The lysates were transferred to a precooled 1.5 ml tube and incubated on ice for 
30 min, followed by centrifugation at 14000 x g for 15 min at 4 °C. The supernatant 
containing the proteins was then transferred into a new precooled 1.5 ml tube and stored at -
80 °C. 
For cell lysis for immunoprecipitation, IP lysis buffer (1x) was used. Cells were washed with 
PBS, scraped in PBS and transferred to a precooled 1.5 ml tube. After centrifugation at 
400 x g for 5 min at 4 °C, the pellet was resuspended in IP lysis buffer, followed by 
sonification twice for 1 min and incubation on a rotator for 1 h at 4 °C. Then, the lysates were 
centrifuged at 14000 x g for 15 min at 4 °C and the supernatant containing the proteins was 
transferred into a new precooled 1.5 ml tube. Protein samples were stored at -80 °C. 
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3.2.8. Determination of protein concentration 
Protein concentrations of the lysates were determined with the Micro BCA™ Protein Assay Kit. 
This assay is based on the formation of a purple-coloured reaction product by two molecules 
bicinchoninic acid (BCA) with a cuprous cation (Cu1+). Cu1+ originates from the reduction of 
Cu2+ by proteins in an alkaline medium. The BCA-Cu1+ complex is water-soluble and can be 
detected with an ELISA reader at 562 nm (Smith et al., 1985). The intensity of the purple 
reaction product is proportional to the protein concentration which can be determined by 
comparing its absorbance to a BSA standard curve, measured in parallel in the range of 0-
40 µg/ml protein. The protein samples were diluted 1:150 in ddH2O and the concentrations 
determined in triplicates. As for the rest, the BCA assay was performed according to 
manufacturer’s instructions. 
 
3.2.9. SDS polyacrylamide gel electrophoresis 
With sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), proteins can 
be separated by their molecular weight due to the SDS in the gel and the reducing 
electrophoresis buffer, which is denaturing the proteins leading to an evenly distributed 
negative charge. The gels were prepared according to the pipette scheme in Table 8. Prior to 
electrophoresis, protein extracts including 6x reducing electrophoresis buffer were heated at 
99 °C for 10 min. Per lane, 20-30 µg total protein extract were loaded on the gel and 
separated by 25 mA per gel.  
Table 8: Pipetting scheme for two discontinuous SDS electrophoresis gels (8.3 cm x 7.3 cm x 1 mm). 
 Separation gel 
6% 
Separation gel 
10% 
Separation gel 
12% 
Collection gel 
5% 
Distilled water 6.9 ml 4.7 ml 3.6 ml 3.52 ml 
Rotiphoresis gel 
30 
3.2 ml 5.4 ml 6.5 ml 0.836 ml 
Tris HCl (pH 
8.8) 
6.0 ml 6.0 ml 6.0 ml - 
Tris HCl (pH 
6.8) 
- - - 0.626 ml 
10% SDS 0.162 ml 0.162 ml 0.162 ml 0.05 ml 
20% APS 0.054 ml 0.054 ml 0.054 ml 0.04 ml 
TEMED 0.012 ml 0.012 ml 0.012 ml 0.005 ml 
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3.2.10. Coomassie Blue staining 
For Coomassie Blue staining, the SDS gel was incubated in Coomassie Blue solution for 1 h at 
RT while shaking, leading to a fixation and staining of the separated proteins. Afterwards the 
gel was destained with destaining solution for approximately 10 min at RT while shaking, 
followed by 10 min washing with distilled water. These two steps were repeated five times. 
Afterwards, the gel was ready for evaluation.  
 
3.2.11. Western blotting 
For western blotting, SDS-PAGE (3.2.9) with 6%, 10% or 12% gels was performed. For 
proteins with a higher molecular weight like DNA-PKcs (470 kDa), lower percentage gels 
(6%) were used and for small proteins like Survivin (16.5 kDa), higher percentage gels (12%) 
were used. Following SDS-PAGE, filter papers and a nitrocellulose membrane soaked in 
transfer buffer were placed in a blotting cassette. Then, the SDS gel was placed on top of the 
membrane followed by more filter papers soaked in transfer buffer. After the blotting cassette 
was locked, protein transfer was performed at 1.3 A and up to 25 V per gel for 10 min or 
15 min for DNA-PKcs. To confirm the correct protein transfer and equal loading of the SDS 
gel, the membranes were incubated in Ponceau S solution for 2 min, subsequently washed 
with distilled water and destained with TBS-T. For blocking, the membranes were incubated 
in 5% milk powder/TBS-T at RT for 1 h, followed by an overnight incubation at 4 °C with the 
respective primary antibodies (Table 1), diluted in 5% BSA/TBS-T. After incubation with the 
primary antibodies, the membranes were washed three times with TBS-T for 10 min at RT. 
Thereafter, horseradish peroxidase-conjugated goat anti-rabbit and goat anti-mouse 
secondary antibodies (Table 3), diluted in 5% milk powder/TBS-T were applied to the 
membranes for 1 h at RT. Membranes were washed again three times with TBS-T and once 
with TBS for 10 min at RT before they were ready for detection. Next, the membranes were 
placed on an imaging tray and incubated for 2 min with working solutions of an enhanced 
chemiluminescent (ECL) substrate. Odyssey Fc Imaging System and Image Studio Version 5.2 
Software were used for detection of the chemiluminescent signal.  
 
3.2.12. Immunoprecipitation 
For co-immunoprecipitation 50 µl of the magnetic beads were washed once with PBS, before 
3 µg of the respective antibody diluted in PBS was added, followed by incubation on a rotator 
at 4 °C for 6 h. A non-specific mouse mAb IgG1 isotype antibody was used as a control. In the 
meantime, cells were harvested on ice (3.2.7) and protein concentrations were determined 
using BCA (3.2.8). After the 6 h incubation, the antibodies bound to the magnetic beads were 
cross-linked using BS3. Therefore, the Ig-coupled antibody was washed twice with 200 µl 
conjugation buffer (20 mM sodium phosphate, 0.15 M NaCl), followed by incubation in 
250 µl BS3 (5 mM in conjugation buffer) for 30 min at RT while rotating. Adding 12.5 µl 
quenching buffer (1 M Tris HCl, pH 7.5) and incubating for 15 min at RT while rotating 
quenched the cross-linking reaction. Beads were then washed three times with 200 µl PBS-T, 
before 2 mg of the respective protein was added. After incubation overnight at 4 °C while 
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rotating and washing three times with ice-cold PBS, beads were resuspended in 26 µl lysis 
buffer and 9 µl loading buffer. The samples were heated for 10 min at 99 °C with thorough 
mixing in between prior to SDS-PAGE and western blotting.  
 
3.2.13. Vector cloning 
 
Polymerase chain reaction (PCR) 
Either existing plasmids encoding the gene of interest or cDNA were used as templates for 
insertion of the genes of interest into the plasmids. 50 ng of plasmid or 2.5 µl of cDNA were 
used as template along with 5 µl 10x Buffer plus 2.5 µl forward and reverse primers (10 µM, 
3.1.11) plus 1 µl dNTPs (10 mM each) plus 1 µl PfuUltra HF adjusting to a total volume of 
50 µl with RNase/DNase-free water per reaction. The PCR conditions are shown in Table 9. 
Annealing temperature and elongation time were adjusted according to primer melting 
temperature and length of template respectively. The annealing temperature was set at the 
lowest melting temperature of one of the primers, elongation time was calculated with 1 min 
per kb of the amplified template. 
 
Table 9: Standard PCR protocol for DNA amplification with PfuUltra HF. Annealing temperature and 
elongation time were adjusted according to primer melting temperature and length of template 
respectively. 
Temperature [°C] Time [min:sec]  
95 2:00  
95 0:30 
35x According to melting temp. 1:00 
72 1:00/kb 
72 15:00  
4 ∞  
 
The PCR samples were purified using the NucleoSpin® Gel and PCR Clean-Up Kit following 
manufacturer’s instructions. 
 
Agarose gel electrophoresis 
DNA fragments were separated via agarose gel electrophoresis. The agarose gels were 
prepared using 60 ml of a 1% agarose gel/TAE buffer solution, supplemented with 5 µl 
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peqGREEN in order to visualize DNA. Before loading on the gel, DNA was mixed with an 
appropriate volume of DNA loading dye (5x). Gel electrophoresis was performed at 80 V for 
approximately 1 h. Thereafter, DNA was visualized using the Odyssey Fc Imaging System and 
Image Studio Version 5.2 Software. The size of the DNA was determined with the GelPilot 1kb 
Plus DNA ladder. 
 
Restriction enzyme digestion 
For restriction enzyme digestion approximately 10 µg of the purified PCR samples and the 
respective plasmids were used with 20 U of each restriction enzyme, 5 µl NEBuffer #1 (10x) 
and 0.5 µl BSA (100x) and adjusted to a total volume of 50 µl with RNase/DNase-free water. 
The digestions were incubated at 37 °C overnight.  
The digested inserts were purified using the NucleoSpin® Gel and PCR Clean-Up Kit 
following the manufacturer’s instructions and eluted in 30 µl RNase/DNase-free water. For 
purification of the linearized plasmid backbones, the digestion reaction batches were loaded 
and separated on a 1% agarose gel. The plasmid of the correct size was then extracted from 
the gel and also purified by using the NucleoSpin® Gel and PCR Clean-Up Kit and eluted in 
50 µl RNase/DNase-free water.  
 
Ligation 
Ligation reactions contained the plasmid backbone DNA and the respective insert, 1 µl T4 
DNA ligase and 1 µl T4 ligase buffer (10x) adjusted to a total volume of 10 µl with 
RNase/DNase-free water per reaction, followed by incubation overnight at 14 °C. Equimolar 
rations for vector and insert were calculated as follows: 
𝑛𝑔 𝑖𝑛𝑠𝑒𝑟𝑡 =  𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 × 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 (𝑏𝑝)𝑠𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 (𝑏𝑝)  
For ligations, an insert to vector ratio of 3:1 was used. 
 
Preparation of competent Escherichia coli (E. coli) 
For the preparation of competent E. coli DH5α, 5 ml LB medium were inoculated with a cryo 
stock of E. coli DH5α, followed by overnight incubation at 37 °C while shaking at 250 rpm. 
The following day, 400 µl of the overnight culture was transferred into 200 ml LB medium. 
Incubation at 37 °C while shaking at 250 rpm was continued until an OD600 of 0.2 was 
reached. The cells were then pelleted at 4100 x g and 4 °C for 10 min and resuspended in 
20 ml MOPS I buffer. After 10 min incubation on ice, the cells were centrifuged again at 
4100 x g and 4 °C for 10 min, followed by resuspension of the pellet in 20 ml MOPS II buffer. 
Due to the CaCl2, the membrane permeability is changed which leads to the possibility of DNA 
uptake through the membrane (Mandel and Higa, 1970). After another incubation at 4 °C for 
30 min and centrifugation at 4100 x g and 4 °C for 10 min, the pellet was resuspended in 2 ml 
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MOPS II buffer and aliquoted into 200 µl portions in precooled 1.5 ml tubes containing 50 µl 
glycerol. After mixing carefully, the competent cells were snap frozen in liquid nitrogen and 
stored at -80 °C. 
 
Transformation 
For the transformation of chemically competent E. coli DH5α cells with plasmids, 50 µl cells 
per transformation were thawed on ice and mixed with plasmid DNA. In case of previously 
ligated plasmids, 3 µl of the ligation reaction batch was used, for retransformation of 
plasmids, 50 ng DNA was used. DNA and cells were mixed carefully and incubated on ice for 
20 min, followed by a heat-shock for 45 sec at 42 °C in a water bath. After that, the cells were 
cooled on ice for 2 min, before 200 µl sterile LB medium was added. Prior to plating on LB-
agar plates containing the appropriate antibiotics, the cells were regenerated for 60 min at 
37 °C while shaking. The plates were incubated overnight at 37 °C. 
 
Plasmid mini-preparation 
For plasmid mini-preparation, 5 ml LB medium was inoculated with one colony of the 
transformed E. coli DH5α cells. After overnight incubation at 37 °C with agitation, plasmid 
isolation with 4 ml from the overnight culture was performed, using the NucleoSpin® 
Plasmid Kit and following the manufacturer’s instructions. For each transformation approach, 
at least three colonies were used. After that, the concentrations of the isolated plasmids were 
measured using spectrophotometry. The plasmids were stored at -20 °C.  
 
Control digestion and sequencing 
To test whether the isolated plasmids have incorporated the correct insert, a control digestion 
was performed using the same restriction enzymes as for the cloning. After incubation 
overnight at 37 °C, the resulting fragments were analysed via agarose gel electrophoresis. The 
plasmids showing the correct band pattern were sent for sequencing. Sequencing was 
performed by Eurofins Genomics (Ebersberg), the primers used are shown in Table 7.  
 
Plasmid midi-preparation 
The plasmids with the correct sequence were then produced in a higher scale using midi-
preparation. Therefore, 100 µl of the remaining bacteria culture of the mini-preparation was 
used to inoculate 100 ml LB medium containing the appropriate antibiotics. After incubation 
overnight at 37 °C with agitation, the plasmids were isolated using the NucleoBond® Xtra 
Midi Plus EF Kit following manufacturer’s instructions. Thereafter, the DNA concentrations 
were measured using spectrophotometry. The plasmids were stored at -20 °C. 
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3.2.14. Production of bacterial GST fusion proteins and GST preparation 
With glutathione S-transferase (GST) fusion proteins protein-protein interactions can be 
verified. Consequently, the GST encoding sequence is linked directly to the sequence of the 
protein of interest. After transcription and translation in bacteria, a GST fusion protein is 
produced and can be isolated for interaction studies. Due to the high binding affinity of GST 
to glutathione, glutathione coupled sepharose beads can be used for purification of the GST 
fusion protein. 
In this study, the kinase domain of DNA-PKcs was fused to a GST protein. Hence RNA was 
isolated from SW480 cells using the NucleoSpin® RNA kit following the manufacturer’s 
instructions. Next, cDNA was created using an oligo-dT primer and the enzyme reverse 
transcriptase. From this cDNA, PI3K was amplified using PCR and inserted into the 
KpnI/EcoRI restriction sites of the pGEX-5X-3 (including a KpnI restriction site, 3.1.6) vector. 
A detailed cloning procedure was described earlier (3.2.13). E. coli BL-21 transformed with 
the GST fusion proteins was cultivated in 10 ml of selective LB medium over night at 37 °C 
while shaking at 250 rpm. The next day, the overnight culture was transferred into 100 ml 
selective LB medium and incubated for 75 min while shaking at 250 rpm, followed by 
induction with 50 µl IPTG to a final concentration of 1 mM. The interaction of IPTG with the 
lac repressor leads to the expression of the T7 polymerase gene, which then recognises its 
specific promotor resulting in the production of GST fusion protein. After further incubation 
for 1 h while shaking at 250 rpm, bacteria were collected by centrifugation (4100 x g, 15 min, 
4 °C). The pellet was resuspended in 2 ml cold CelLytic B (2x) lysis buffer supplemented with 
1 µl PMSF (0.2 M), 1 µl Na3VO4 (100 mM), 10 µl protease inhibitor (100x), 10 µl lysozyme 
(100 mg/ml), 1 µl Benzonase (250 U/µl) and transferred into a 2 ml tube, followed by 
rotation for 15 min at RT. After centrifugation at 18000 x g for 15 min at 4 °C, the 
supernatant containing the protein fraction was transferred to a new precooled 2 ml tube. To 
isolate the GST fusion proteins, 100 µl of a 50% glutathione sepharose beads suspension were 
added to the protein solution and incubated for 30 min at 4 °C while rotating. The beads were 
ready to use after washing twice with PBS. By centrifugation (2000 x g, 3 min, 4 °C) GST 
fusion protein bound to the beads was isolated, followed by three washing steps with PBS and 
mixing thoroughly to remove unspecific bound proteins. After resuspension in 50 µl PBS, the 
amount of GST fusion protein was determined by SDS-PAGE (3.2.9) and Coomassie Blue 
staining (3.2.10).  
 
3.2.15. GST pulldown assay 
With a pulldown assay, direct interactions between proteins can be detected. Accordingly, the 
protein-coupled GST beads are incubated with cell lysate containing the potential interaction 
partner of the GST fusion protein. Here, the kinase domain of DNA-PKcs (PI3K) was fused to 
GST and investigated regarding an interaction with Survivin which was linked to either an 
EGFP- or a FLAG tag.  
At first, SW480 cells were seeded aiming for a confluency of approximately 80% at 24 h after 
plating in 6-well plates. Before transfection with the K2 Transfection System, medium was 
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exchanged with 1125 µl fresh medium (+ 20% FBS + 1% P/S) and 11.25 µl K2 Multiplier 
were added to each well, followed by incubation for 2 h at 37 °C and 5% CO2. Meanwhile, 
1.6 µg of plasmid DNA were mixed with 67.5 µl serum-free Opti-MEM per transfected 6-well 
(solution A) and 4.5 µl K2 transfection reagent were mixed with 67.5 µl serum-free Opti-MEM 
per transfected well (solution B). Both solutions were carefully mixed and solution A was 
added to solution B respectively followed again by careful mixing. After 20 min incubation at 
RT and 2 h incubation of the cells with K2 Multiplier, 142 µl of the DNA lipid complexes was 
added to the 6-wells and mixed by careful pivoting. The transfected cells were then incubated 
for another 24 h at 37 °C and 5% CO2 prior to seeding in 100 mm dishes for further growth of 
the cells for another 24 h. At 1 h after IR with 4 Gy, SW480 cells were harvested (3.2.7) and 
the lysates were incubated together with the GST fusion protein overnight at 4 °C while 
rotating. Unspecific binding was blocked by addition of 10% BSA (10 mg/ml). After the 
incubation, the glutathione sepharose beads were washed three times with IP lysis buffer. 
Then, beads were resuspended in 24 µl IP lysis buffer and 6x reducing electrophoresis buffer, 
followed by separation via SDS-PAGE (3.2.9). GST fusion proteins or interacting proteins 
were detected with specific antibodies via western blotting (3.2.11).  
 
3.2.16. NanoLuc Binary Technology (NanoBiT®) complementation assay 
The NanoBiT® assay is based on a two-subunit NanoLuc luciferase that can be used for 
intracellular detection of protein-protein interactions. This luciferase consists of a large 
subunit (LgBiT, 17.6 kDa) and a small subunit (SmBiT, 1.3 kDa). The two subunits are fused 
to two interaction partners and when expressed in cells, the interaction of the proteins brings 
the two subunits into close proximity. This leads to the structural complementation of LgBiT 
and SmBiT, generating a functional enzyme that is producing a luminescent signal, which can 
be detected with an ELISA reader. Because of the subunits low affinity to each other, their 
interaction is driven by the behaviour of the fusion partners.  
In order to test all possible combinations, constructs were made encoding LgBiT and SmBiT 
fusions to the N- and C-termini of Survivin and the kinase domain of DNA-PKcs (PI3K), 
resulting in eight different expression constructs. Subsequently, Survivin and PI3K were 
amplified from existing plasmids, using the primers given in Table 5. Standard cloning 
procedure was used as described earlier (3.2.13). 
For the NanoBiT complementation assay HEK-293T cells were transiently transfected with one 
or two plasmids encoding the different NanoBiT constructs. As a transfection reagent, 
Effectene was used. The transfection approaches were set up in 1.5 ml tubes as shown below. 
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Table 10: Composition of the transfection reagents for single or double transfections for the NanoBiT® 
complementation assay. 
Plasmid 
DNA 
Conc. 
plasmid 
DNA 
µl DNA 
µl EC 
buffer 
µl 
Enhancer 
µl 
Effectene 
µl EC 
buffer 
Mock 50 ng/µl - 29.2 0.8 1.5 18.5 
Single 
transfection 
50 ng/µl 1.0 28.2 0.8 1.5 18.5 
Double 
transfection 
50 ng/µl 1.0 + 1.0 27.2 0.8 1.5 18.5 
 
At first, the plasmid DNA was diluted with EC buffer, followed by the addition of enhancer 
and thorough mixing. After incubation at RT for 5 min, 1.5 µl Effectene was diluted in a total 
volume of 20 µl EC buffer for each reaction, mixed thoroughly and added to the DNA 
solutions, followed by 20 min incubation at RT. In the meantime, cells were harvested and 
counted. After the incubation, 50 µl of each transfection reaction was pipetted into a 96-well 
plate and 100 µl of cell suspension including 6 x 104 HEK-293T cells were added and carefully 
mixed. The transfected cells were then incubated for another 24 h at 37 °C and 5% CO2 prior 
to irradiation. 1 h after IR with 4 Gy, cell culture medium was carefully replaced by 100 µl 
serum-free Opti-MEM. To start the luminescence reaction, 25 µl of the Nano-Glo Live Cell 
Reagent (1 volume of Nano-Glo Live Cell Substrate with 19 volumes of Nano-Glo LCS Dilution 
Buffer) was added and mixed by gentle shaking for 10 sec. A 10 min incubation step at 37 °C 
within the TECAN ELISA reader was followed by the luminescence measurement for 
2 sec/well. Analysis of the resulting data was performed using Microsoft EXCEL. 
 
3.2.17. Förster resonance energy transfer assay 
The Förster resonance energy transfer (FRET) was introduced by Theodor Förster in 1948. He 
described that an energy transfer between two fluorophores is possible through non-radiative 
dipol-dipol coupling. Thereby, an excited donor fluorophore can transfer energy to an 
acceptor fluorophore (Förster, 1948; Jares-Erijman and Jovin, 2003; Sun et al., 2013). An 
essential prerequisite is that the two fluorophores have to be within a distance of 10 nm or 
less. In addition, the emission spectrum of the donor fluorophore and the absorption spectrum 
of the acceptor fluorophore have to be overlapping (Clegg, 1995; Jares-Erijman and Jovin, 
2003; Sun et al., 2013). This makes FRET a powerful research tool for measurements of 
protein-protein interactions (Patterson et al., 2000). As fluorophores, green fluorescent 
protein (GFP) colour variants like cyan fluorescent protein (CFP) or yellow fluorescent protein 
(YFP) can be used. By coupling the fluorophores to proteins, interactions of both proteins can 
be investigated in living cells (Selvin, 2000). 
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For FRET analysis, HEK-293T cells were transiently transfected with one or two plasmids 
encoding the different CFP/YFP constructs. As a transfection reagent, Effectene was used. The 
transfection approaches were set up in 1.5 ml tubes as described below. 
 
Table 11: Composition of the single or double transfection reaction batches for FRET analysis. 
Plasmid DNA 
Conc. 
plasmid DNA 
µl DNA 
µl EC 
buffer 
µl 
Enhancer 
µl 
Effectene 
Mock 300 ng/µl - 96.8 3.2 10 
Single transfection 300 ng/µl 1.4 95.4 3.2 10 
Double transfection 300 ng/µl 0.7 + 0.7 95.4 3.2 10 
 
First, the plasmid DNA was diluted with EC buffer, followed by the addition of enhancer and 
thorough mixing. After incubation at RT for 5 min, 10 µl Effectene was added to each 
reaction, mixed thoroughly and incubated for 20 min at RT. In the meantime, cells were 
harvested and counted. After the incubation, 110 µl of each transfection reaction was pipetted 
into a 6-well plate and cell suspension including 5 x 105 HEK-293T cells in 2 ml medium was 
added and carefully mixed. The transfected cells were then incubated for another 48 h at 
37 °C and 5% CO2 prior to irradiation. 1 h after IR with 4 Gy, cells were harvested for flow 
cytometry measurements. Thus, cells were washed once with PBS, detached from the cell 
culture plates with trypsin/EDTA and transferred to a 1.5 ml reaction tube. After 
centrifugation (400 x g, 5 min, 4 °C) and washing once with PBS, cells were resuspended in 
200 µl PBS and stored on ice protected from light until flow cytometry measurement.  
Flow cytometry measurements were performed with the CytoFLEX-S flow cytometer. To 
measure CFP or FRET signals, cells were excited with a laser wavelength of 405 nm and the 
emission was detected with a 450/45 filter for CFP and a 525/40 filter for FRET. For YFP 
measurement, cells were excited with the 488 nm laser and the emission was detected with a 
525/40 filter. To exclude overlapping emission spectra of CFP and YFP fluorescence, a 
compensation matrix was generated before every experiment. For each sample, 
100000 events were measured. The gates were set according to flow cytometry-based FRET 
described by Banning and colleagues (Banning et al., 2010). Analysis of the resulted data was 
performed with CytExpert software version 1.2.11.0. 
 
3.2.18. Immunofluorescence staining and imaging 
Cells were seeded on glass coverslips in 6-well plates and transfected with siRNA 24 h later. 
48 h after siRNA transfection, the 6-well plates were irradiated with doses ranging from 1-
4 Gy. At different time points (15 min, 30 min and 24 h) after irradiation, cells were washed 
with ice cold PBS and fixed/permeabilized for 15 min with 3.7% formaldehyde/0.25% Triton 
X-100 in PBS. After three washing steps with PBS for 10 min each, cells were blocked with 5% 
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BSA in PBS for 60 min. Primary antibodies (Table 1) were diluted in blocking solution and 
incubated for 1 h followed by three 10 min washing steps with PBS. Appropriate secondary 
antibodies (Table 2) were also diluted in blocking solution and incubated for 1 h in the dark. 
Subsequently, the coverslips were washed three times with PBS, the nuclei were 
counterstained with DAPI solution (600 ng/ml) and were mounted onto glass slides with 
Vectashield. Images were acquired using an AxioImager Z1 microscope, equipped with an 
Axiocam MRc camera and Axio Vision Imager Software 4.6.2. For quantification, 40 nuclei 
were evaluated from at least three independent experiments and unified to one data point.  
 
3.2.19. Homologous recombination assay 
With the Homologous Recombination Assay Kit, HR efficiency in Survivin depleted cells was 
quantified in a non-radioactive, real-time PCR-based approach. Therefore, cells were co-
transfected with two different plasmids each with a different mutation in its lacZ coding 
region. A recombination of these two plasmids leads to a recombined plasmid with a 
functional lacZ sequence (Ohba et al., 2014). This recombined plasmid can be quantified with 
specific primers by real-time PCR using isolated genomic DNA of the co-transfected cells as 
template.  
For the assay, 0.5 x 105 cells were seeded in 24-well plates and transfected with Survivin 
siRNA (3.2.3) 24 h later. 12 h before the highest degree of Survivin depletion, the cells were 
transfected with the HR assay plasmids using Effectene transfection reagent. The transfection 
reaction batches were set up in 1.5 ml tubes as shown in Table 12. As positive control, a 
plasmid encoding the functional lacZ gene was used and as negative control, the cells were 
transfected with just one of the lacZ-mutated plasmids. 
 
Table 12: Composition of the single or double transfection reactions for the homologous recombination 
assay. 
 Plasmid µl DNA 
µl EC 
buffer 
µl 
Enhancer 
µl 
Effectene 
Positive control  10 50 1.6 5 
Negative control dl-1 / dl-2 10 50 1.6 5 
Double transfection dl-1 + dl-2 10 40 1.6 5 
 
First, 0.5 µg plasmid DNA was diluted in EC buffer, followed by the addition of enhancer and 
thorough mixing. After incubation at RT for 5 min, 5 µl Effectene were added to each reaction 
and mixed thoroughly. Following 20 min incubation at RT, cells were supplied with fresh 
medium before adding the transfection complexes dropwise to the cells. Cells were irradiated 
with 4 Gy directly after plasmid transfection and genomic DNA was isolated from the 
transfected cells after 12 h incubation using the standard protocol for human or animal tissue 
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and cultured cells of the NucleoSpin® Tissue Kit. The genomic DNA was eluted in 25 µl 
RNase/DNAse-free water and the concentrations were measured using spectrophotometry. 
For detection of the relative plasmid quantity, real-time PCR was performed using 50 ng DNA 
diluted in 8 µl RNase/DNAse-free water, 2 µl primers (concentration was not specified by the 
manufacturer) and 10 µl PerfeCTa® SYBR® Green SuperMix. The “universal primers” were 
used for amplification of the plasmid backbone which served as normalization, whereas the 
“assay primers” amplified the recombined plasmid. The real-time PCR protocol for 
amplification is given in Table 13. 
 
Table 13: Protocol for real-time PCR used for amplification of the homologous recombination product. 
Step Temperature [°C] Time [min:sec]  
1 95 3:00  
2 95 0:15 
40x 3 61 0:30 
4 72 1:00 
Detection of fluorescence 
Detection of melting curves 
 
CT values were exported to Microsoft Excel and the HR efficiency was calculated as 
normalized fold expression using the ΔΔCT method (Livak and Schmittgen, 2001). The CT of 
the negative control siRNA treated cells was used to calculate ΔCT. ΔCT of the recombined 
plasmids amplified with “assay primers” was normalized to the ΔCT of the backbone plasmids 
amplified with “universal primers”. ΔΔCT was calculated using the following formula: 
ΔΔC! = 2!! !"#$%"&  !""!# !"#$%" !!! !"#$%&  !""!# !"#$%"2!! !"#$%"&  !"#$%&'() !"#$%" !!! !"#$%&  !"#$%&'() !"#$%"  
 
3.2.20. DNA-PK activity assay 
For analysis of DNA-PK activity, two different methods were applied: the SignaTECT® DNA-
Dependent Protein Kinase Assay and the autophosphorylation measurement of DNA-PKcs at 
its Ser2056 phosphorylation site.  
 
SignaTECT® DNA-Dependent Protein Kinase Assay 
This kinase assay is based on the phosphorylation of a biotinylated p53-derived peptide 
substrate by DNA-PK with [γ-32P] ATP. This biotinylated peptide substrate can then be spotted 
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on a biotin capture membrane for detection of the incorporated 32P into the p53-derived 
peptide.  
The SignaTECT® DNA-Dependent Protein Kinase Assay was performed following the 
manufacturer’s instructions. For each reaction, 25 µg protein from nuclear extracts was used. 
Nuclear extracts were prepared with the Nuclear Complex Co-IP Kit according to 
manufacturer’s protocol and protein concentrations were determined (3.2.8). The amount of 
incorporated 32P into the p53-derived peptide substrate was determined by liquid scintillation 
counting. 
 
Autophosphorylation of DNA-PKcs 
S2056 is an autophosphorylation site of DNA-PK that was shown to be autophosphorylated in 
response to ionizing radiation (Chen et al., 2005; Wechsler et al., 2004). To analyse this 
autophosphorylation site, the respective cell lysates were subjected to SDS-PAGE (3.2.9) and 
western blotting (3.2.11), using antibodies directed against DNA-PKcs and pDNA-PKcs S2056 
(Table 1). 
 
3.2.21. Protein docking analysis 
To predict the interaction interfaces between Survivin and DNA-PKcs, the docking programs 
Schrödinger Suite (Schrödinger, LLC, New York City, NY, USA) and PatchDock (Schneidman-
Duhovny et al., 2005) have been used. PIPER is the protein-protein docking module of 
Schrödinger Suite and its methodology is carried out in two steps: conformational sampling 
followed by structural clustering to identify and rank the probability of docked protein poses.  
For the first step, PIPER employs an efficient FFT (Fast Fourier Transform) approach that 
makes it possible to evaluate a high number of poses. Generated and scored poses simple use 
atomistic energy function that can efficiently separate potentially acceptable poses from those 
that are very unlikely. Typically, 70000 poses are evaluated, and from these the 1000 best 
scoring poses are kept for the second step. In the second step, the 1000 poses are clustered 
based on structure. Then, the member of each cluster with the nearest neighbours is taken as 
representative of that cluster.  
The second docking program used was PatchDock, a geometry-based molecular docking 
algorithm. The aim of this algorithm is to find docking transformations that yield good 
molecular shape complementarity. When applied, such transformations induce wide interface 
areas and small amounts of steric clashes. A wide interface is ensured to include several 
matched local features of the docked molecules that have complementary characteristics. Each 
candidate of the docked molecules is further evaluated by a scoring function that considers 
geometric fit and atomic desolvation energy.  
Pre-processing steps such as filling the missing hydrogen atoms, side chains, loops, cap-
termini, creation of disulphide bonds and energy minimizations were performed before the 
docking analyses in order to obtain more native structures of the proteins.  
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The top 100 docked poses were then post-processed and refined by the FireDock program 
(Andrusier et al., 2007; Mashiach et al., 2008) in order to generate a near-native docking 
structure. The FireDock algorithm performs side-chain optimization and rigid-body 
minimization. After refinement, the interactions between residues were determined according 
to their binding energies (ΔG) by using the GROMOS96 (BIOMOS b.v, Zürich, Switzerland) 
and PocketQuery (Camacho Lab, University of Pittsburgh, PA, USA) programs as well as their 
distances by DeepView–Swiss-PDBViewer (Guex and Peitsch, 1997). The interaction pairs 
with higher ΔG values and distances <5 Å between side chain hydrogen atoms were qualified 
as potential interactors.  
 
3.2.22. Data analysis 
Experimental data are presented as mean ± standard error of the mean (SEM). At least three 
independent experiments were performed. A two-sided unpaired Student’s t-test was 
performed using Microsoft Excel software to test statistical significance. Results were 
considered statistically significant when a p-value less than 0.05 was reached, more significant 
with p < 0.01 and highly significant with p < 0.001, respectively. 
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4. Results 
 
4.1. The impact of Survivin on the DNA double-strand break repair 
Previous work has shown a decreased DNA double-strand break repair after Survivin 
knockdown in colorectal cancer and glioblastoma cell lines (Capalbo et al., 2010; Reichert et 
al., 2011). One aim of this study was to further investigate which DNA DSB repair pathway is 
affected by Survivin as well as the exact molecular mechanism underlying this inhibition. 
 
4.1.1. Survivin depletion impacts on the number of DNA double-strand breaks after 
irradiation with X-rays 
To analyse the impact of Survivin on radiation induced DNA damage induction and repair, 
immunofluorescence analysis of the phosphorylation of the histone variant H2AX on serine 
139 (γH2AX) and the recruiting of p53-binding protein 1 (53BP1) as markers for the presence 
of DNA DSBs were applied. For that purpose, SW480 colorectal and A2780 ovarian cancer cell 
lines were plated onto glass coverslips and transfected with Survivin siRNA or control siRNA. 
As a control, mock treated cells were analysed. 48 h after transfection, cells were irradiated 
with single doses of 1 or 4 Gy. γH2AX and 53BP1 foci formation was quantified 15 min and 
30 min after IR with 1 Gy and residual foci were counted 24 h after irradiation with 4 Gy.  
In SW480 colorectal cancer cells, the number of γH2AX/53BP1 foci at early time points 
(15 min, 30 min) was significantly increased after irradiation with 1 Gy upon knockdown of 
Survivin (Figure 10C). Residual DNA damage (24 h) was also significantly increased in 
SW480 cells upon Survivin knockdown and irradiation with 4 Gy (Figure 10B). The siRNA-
mediated knockdown of Survivin was verified by western blotting (Figure 10A). Exemplary 
immunofluorescence staining of γH2AX and 53BP1 foci is depicted in Figure 10D. 
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Figure 10: Treatment with Survivin-specific siRNA results in increased numbers of γH2AX and 53BP1 foci 
in irradiated SW480 cells. Survivin knockdown was verified by western blotting. β-actin served as a 
loading control (A). SW480 cells were irradiated 48 h after siRNA transfection with 1 Gy or 4 Gy. At 24 h 
after IR with 4 Gy (B) as well as 15 min and 30 min after IR with 1 Gy (C), cells were fixed and stained 
for DAPI, γH2AX and 53BP1. For each condition, γH2AX/53BP1 foci were quantified from at least 40 
nuclei and combined to a single data point. (D) Exemplary immunofluorescence staining of γH2AX, 
53BP1 and DAPI. Data represent means ± SEM from at least three independent experiments. Statistical 
significances are indicated by asterisks: * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
In the ovarian cancer cell line A2780, western blotting analysis showed a strong knockdown 
of Survivin in cells transfected with Survivin siRNA as compared to control siRNA and mock 
treated cells (Figure 11A). Upon Survivin knockdown and irradiation with 4 Gy, residual DNA 
damage (24 h) was significantly increased in A2780 cells (Figure 11B). The numbers of 
γH2AX/53BP1 foci at early time points (15 min, 30 min) were also increased after irradiation 
with 1 Gy upon knockdown of Survivin (Figure 11C).  
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Figure 11: Treatment with Survivin-specific siRNA results in increased numbers of γH2AX and 53BP1 foci 
in irradiated A2780 cells. Survivin knockdown was verified by western blotting. β-actin served as a 
loading control (A). A2780 cells were irradiated 48 h after siRNA transfection with 1 Gy or 4 Gy. At 24 h 
after IR with 4 Gy (B) as well as 15 min and 30 min after IR with 1 Gy (C), cells were fixed and stained 
for DAPI, γH2AX and 53BP1. For each condition, γH2AX/53BP1 foci were quantified from at least 40 
nuclei and combined to a single data point. Data represent means ± SEM from at least three 
independent experiments. Statistical significances are indicated by asterisks: * p < 0.05, *** p < 0.001. 
 
In summary, Survivin knockdown results in an increased number of DNA DSBs at 15 min and 
30 min after irradiation with 1 Gy, in both, colorectal and ovarian cancer cells. Quantification 
of γH2AX/53BP1 foci 24 h after irradiation with 4 Gy further indicates an increased 
modulation of DNA damage repair upon Survivin depletion. These findings thus confirmed an 
impact of Survivin in radiation-induced DNA double-strand break repair. 
 
4.1.2. Involvement of Survivin in the non-homologous end-joining repair pathway 
In order to investigate in which DNA repair pathway Survivin is involved, γH2AX/53BP1 foci 
were next quantified in a BRCA2 homozygously deleted ovarian cancer cell line (OVSAHO) 
(Domcke et al., 2013). By loading Rad51 to the resected DNA regions (Sorensen et al., 2005), 
BRCA2 has a crucial role in HR and due to the lack of BRCA2, the OVSAHO cell line is 
incapable in performing HR.  
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In OVSAHO ovarian cancer cells, western blotting analysis showed an efficient knockdown of 
Survivin in cells transfected with Survivin siRNA compared to control siRNA and mock treated 
cells (Figure 12A). Survivin knockdown and irradiation with 4 Gy resulted in significantly 
increased residual DNA damage (24 h) (Figure 12B). The number of γH2AX/53BP1 foci at 
early time points (15 min, 30 min) was also increased significantly after irradiation with 1 Gy 
upon knockdown of Survivin (Figure 12C). 
 
Figure 12: Treatment with Survivin-specific siRNA results in increased numbers of γH2AX and 53BP1 foci 
in irradiated OVSAHO cells. Survivin knockdown was verified by western blotting. β-actin served as a 
loading control (A). OVSAHO cells were irradiated 48 h after siRNA transfection with 1 Gy or 4 Gy. At 
24 h after IR with 4 Gy (B) as well as 15 min and 30 min after IR with 1 Gy (C), cells were fixed and 
stained for DAPI, γH2AX and 53BP1. For each condition, γH2AX/53BP1 foci were quantified from at 
least 40 nuclei and combined to a single data point. Data represent means ± SEM from at least three 
independent experiments. Statistical significances are indicated by asterisks: ** p < 0.01, *** p < 0.001. 
 
Data given in Figure 12 indicate a hampered DNA DSB repair in BRCA2 deficient OVSAHO 
cells upon Survivin knockdown. Since these cells are not able to repair DSBs with HR and 
consequently use NHEJ to repair DSBs, it is most likely that Survivin does not impact on HR 
but on the NHEJ repair pathway.  
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4.1.3. Analysis of the involvement of Survivin in the homologous recombination 
repair pathway 
To further confirm, that HR is not involved in Survivin mediated modulation of DNA DSB 
repair, an additional HR assay was performed. In this assay, HR efficiency was quantified in a 
non-radioactive, real-time PCR-based approach. The assay is based on the co-transfection of 
two plasmids, each with a different mutation in its lacZ coding region. A recombination of 
these two plasmids results in a recombined plasmid with a functional lacZ sequence (Ohba et 
al., 2014) that can be quantified with specific primers via real-time PCR.  
In order to test the applicability of the assay, SW480 cells were transfected with only one 
lacZ-mutated plasmid as negative control and a plasmid including a functional lacZ sequence 
as a positive control (Figure 13C). In non-irradiated SW480 cells, Survivin knockdown did not 
result in a decreased HR efficiency compared to mock and control siRNA treated cells (Figure 
13A). Upon irradiation with 4 Gy and siRNA-mediated Survivin depletion, a slight but not 
significant decrease in HR activity could be measured compared to mock and control siRNA 
treated cells (Figure 13B).  
 
Figure 13: Homologous recombination (HR) assay displays no involvement of Survivin in HR in SW480 
cells. To measure HR efficiency, a real-time PCR-based HR assay was used. This assay is based on the 
homologous recombination of two co-transfected plasmids, each with a different mutation on its lacZ 
gene. By using specific primers and real-time PCR, the correct recombination of the lacZ sequence can 
be quantified. Cells were transfected with Survivin siRNA (green), control siRNA (black) or mock treated 
(white) and partly irradiated with 4 Gy (B). Non-irradiated cells (0 Gy) are shown in (A). (C) Transfection 
of only one lacZ-mutated plasmid served as negative control and a plasmid including a functional lacZ 
sequence as a positive control. Data represent means ± SEM from at least three independent 
experiments. 
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In conclusion, these results further indicate that Survivin is probably not involved in the 
modulation of the HR repair pathway.  
 
4.2. Establishment of cell lines, stably expressing a Survivin-ΔXIAP deletion mutant 
To analyse the impact of the XIAP binding site of Survivin on radiation induced DNA double-
strand break repair, a colorectal cancer and a glioblastoma cell line were stably transfected 
with different Survivin constructs expressing the wild type protein (Surv. wt, covering amino 
acid residues (AA) 1-142) and the deletion mutant of the XIAP binding site (ΔXIAP, AA 1-14 
and 39-142), each fused in frame to EGFP at the C-terminus of the recombinant proteins 
(Figure 14A). Cells stably transfected with a sole EGFP construct served as a control. The 
Survivin constructs and the stably transfected SW480 colorectal cancer cells were kindly 
provided by Dr. Chrysi Petraki. The glioblastoma cell line LN-229 was stably transfected with 
the Survivin constructs within this thesis.  
In order to ascertain that effects analysed in Survivn mutant cells arise from the recombinant 
constructs, endogenous Survivin was depleted with Survivin-directed siRNA, targeting only 
the endogenous and not the recombinant Survivin. The knockdown of endogenous Survivin as 
well as the expression of EGFP, Surv. wt and Survivin-ΔXIAP in SW480 cells (Figure 14B) and 
LN-229 cells (Figure 14C) were confirmed by western blotting. 
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Figure 14: Stable transfection of colorectal cancer (SW480) and glioblastoma (LN-229) cells with 
Survivin-EGFP fusion constructs. (A) Schematical representation of enhanced green fluorescent protein 
(EGFP), Survivin wild type-EGFP (Surv. wt) and Survivin XIAP binding site deletion mutant fused to EGFP 
(ΔXIAP). The expression of EGFP, Surv. wt and ΔXIAP protein as well as the siRNA-mediated 
knockdown of endogenous Survivin in SW480 (B) and LN-229 (C) was confirmed by western blotting. β-
actin served as a loading control.  
 
4.3. Interaction of Survivin with DNA-PKcs, a key player of the non-homologous 
end-joining DNA repair pathway 
Survivin has been shown to participate in the non-homologous end-joining DNA repair 
pathway by interacting with repair factors such as DNA-PKcs (Capalbo et al., 2010; Reichert 
et al., 2011). Thus, the following experiments were performed to characterise in more detail 
the interaction of Survivin with DNA-PKcs.  
 
4.3.1. Interaction of the Survivin-ΔXIAP mutant with DNA-PKcs 
A first set of experiments was performed to analyse whether the deletion of the XIAP binding 
site impacts on the interaction between Survivin and DNA-PKcs. In line with that, SW480 
colorectal cancer and LN-229 glioblastoma cells stably overexpressing the Survivin wt, 
Survivin-ΔXIAP and EGFP constructs were used for immunoprecipitation assays to unravel an 
interaction.  
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As depicted in Figure 15 and Figure 16, DNA-PKcs was found to precipitate with Surv. wt but 
not with EGFP or the ΔXIAP construct in both SW480 colorectal cancer cells and LN-229 
glioblastoma cells. 
 
Figure 15: In immunoprecipitation (IP) experiments with SW480 lysates, DNA-PKcs was found to 
precipitate with recombinant Survivin wt but not with the ΔXIAP deletion mutant after irradiation with 
4 Gy. DNA-PKcs-IPs were performed with lysates of SW480 cells stably overexpressing EGFP (as a 
control), recombinant Survivin wt and the ΔXIAP deletion mutant after irradiation with 4 Gy. Co-
immunoprecipitated proteins were detected via western blotting. Non-specific isotype antibody 
(immunoglobulin G, IgG) served as additional control. Input showed the respective proteins in cell 
lysates. DNA-PKcs was detected with an anti-DNA-PKcs antibody while recombinant Survivin-EGFP 
constructs were detected with an anti-GFP antibody.  
 
 
Figure 16: In immunoprecipitation (IP) experiments with LN-229 lysates, DNA-PKcs was found to 
precipitate with recombinant Survivin wt but not with the ΔXIAP deletion mutant after irradiation with 
4 Gy. DNA-PKcs-IPs were performed with lysates of LN-229 cells stably overexpressing EGFP (as a 
control), recombinant Survivin wt and the ΔXIAP deletion mutant after irradiation with 4 Gy. Co-
immunoprecipitated proteins were detected via western blotting. Non-specific isotype antibody 
(immunoglobulin G, IgG) served as additional control. Input showed the respective proteins in cell 
lysates. DNA-PKcs was detected with an anti-DNA-PKcs antibody while recombinant Survivin-EGFP 
constructs were detected with an anti-GFP antibody.  
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In conclusion, these data indicate that Survivin indeed interacts with the DNA-PKcs on a 
molecular level. Moreover, the XIAP binding site of Survivin seems to be an essential 
determinant for the protein-protein interaction between Survivin and DNA-PKcs.  
 
4.3.2. Interaction of Survivin with the kinase domain (PI3K) of DNA-PKcs 
After showing a probable direct involvement of the XIAP binding site of Survivin in the 
interaction with DNA-PKcs, we next asked on the localisation of the putative binding regions 
of DNA-PKcs. In 2003, Chen and colleagues reported that Survivin binds directly to the 
catalytic domain of Aurora-B and thereby stimulates Aurora-B kinase activity (Chen et al., 
2003). In analogy, we decided to investigate an interaction of Survivin with the kinase 
domain of DNA-PKcs, the PI3K domain.  
 
Survivin binds to the PI3K domain of DNA-PKcs in pulldown assay  
At first, the interaction of Survivin with the PI3K domain of DNA-PKcs was analysed by a GST 
pulldown assay. Experimentally, the PI3K domain was fused to GST and expressed in the 
IPTG-inducible E. coli strain BL21 (Figure 17A). After purification of GST-PI3K protein via 
glutathione coupled sepharose beads, the production of GST and GST-PI3K was analysed by 
SDS-PAGE and Coomassie Blue staining (Figure 17B). Finally, GST (as a control) and GST-
PI3K were incubated with cell lysates of SW480 cells expressing Survivin-EGFP or FLAG-
Survivin fusion constructs.  
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Figure 17: Expression of GST fusion constructs in E. coli BL21 for GST pulldown assay. (A) Schematic 
methodology of the cloning procedure of the DNA-PKcs kinase domain (PI3K) in the pGEX-5X-3 vector 
and its expression in E. coli. (B) GST fusion constructs were purified with glutathione coupled sepharose 
beads and analysed via SDS-PAGE and Coomassie Blue staining. Different amounts of the GST protein 
solution (1  l, 2  l and 5  l) and 10  l of the GST-PI3K protein solution were loaded onto the gel. Red 
frame indicates GST-PI3K fusion construct in the corresponding lane.  
 
After purification of the GST fusion proteins, a very prominent GST band was detected, 
independently of whether 1 µl, 2 µl and 5 µl were loaded onto the SDS gel. In the GST-PI3K 
fraction, only a weak band was visible at the correct height of approximately 55 kDa 
(indicated by a red frame in Figure 17B). After assessing equivalent amounts of GST and GST-
PI3K in a specific volume of the protein solution, approximately the same amounts of GST and 
GST-PI3K were used for incubation with the SW480 lysates.  
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Figure 18: GST pulldown assay in SW480 cells shows binding of Survivin to the PI3K domain of DNA-
PKcs. GST (as a control) and GST-PI3K fusion construct were expressed in E. coli BL21 and purified with 
glutathione coupled sepharose beads before incubation with SW480 cells irradiated with 4 Gy, 
expressing Survivin-EGFP (A) or FLAG-Survivin (B) fusion proteins. Input showed the respective proteins 
in cell lysates. GST fusion proteins were detected using an anti-GST antibody, Survivin-EGFP with an anti-
GFP antibody, endogenous Survivin with an anti-Survivin antibody and FLAG-Survivin with an anti-FLAG 
antibody. 
 
After incubation of GST-PI3K with cell lysates of SW480 cells irradiated with 4 Gy and 
pulldown of GST-PI3K via glutathione coupled sepharose beads, both, Survivin-EGFP and 
endogenous Survivin were detected to interact with the GST-PI3K fusion construct (Figure 
18A). By using EGFP and GST controls, one can rule out that the interaction was induced by 
the presence of the tags (Figure 18A). After incubating GST-PI3K with cell lysates of 
irradiated SW480 expressing FLAG-Survivin, the latter was confirmed binding to GST-PI3K 
(Figure 18B).  
 
Survivin binds to the PI3K domain of DNA-PKcs in NanoBiT complementation assay  
To confirm the results from the pulldown assays, interaction analysis with NanoBiT 
complementation assay was performed. The NanoBiT assay is based on a two-subunit 
luciferase. Each of the subunits can be fused to an interaction partner. If the fusion constructs 
are expressed in cells, the two subunits come into close proximity when the proteins are 
interacting. This leads to a structural complementation of the subunits, generating a 
functional luciferase that is producing a detectable luminescent signal (Figure 19).  
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Figure 19: Schematic representation of the NanoBiT complementation assay principle. The large (LgBiT) 
and the small (SmBiT) subunit of a two-subunit NanoLuc luciferase are fused to two interaction partners 
(PI3K and Survivin). When expressed in cells, an interaction of the two proteins brings the two subunits 
into close proximity, leading to the structural complementation of LgBiT and SmBiT. This results in a 
functional enzyme that is producing a luminescent signal.  
 
To establish the best combinations, plasmid constructs were created encoding LgBiT and 
SmBiT fusions to the N- and C-termini of Survivin and PI3K kinase domain, resulting in eight 
different expression constructs. After successful cloning of all constructs, HEK-293T cells were 
transfected and western blotting was performed in order to check whether the constructs are 
produced in the cells. Due to a lacking anti-PI3K antibody, only the Survivin constructs were 
analysed by western blotting (Figure 20).  
 
Figure 20: Expression of Survivin-LgBiT and Survivin-SmBiT constructs in HEK-293T cells. Western blot 
confirmation of Survivin-LgBiT and Survivin-SmBiT expression for NanoBiT complementation assay. Anti-
Survivin antibody was used to detect fusion protein expression, β-actin served as loading control. 
 
All four Survivin constructs showed a strong signal in the western blot and were used together 
with the four PI3K constructs in order to test all combinations of the constructs to determine 
the optimal orientation for fusing Survivin and PI3K to LgBiT and SmBiT. After testing all 
combinations in the NanoBiT assay, Survivin-SmBiT and LgBiT-PI3K turned out to be the 
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optimal construct combination for this assay (data not shown) and accordingly were used for 
all continuative NanoBiT experiments.  
 
Figure 21: NanoBiT complementation assay for protein-protein interaction analysis indicates an 
interaction between Survivin and the PI3K domain of DNA-PKcs. To measure an interaction, HEK-293T 
cells were transiently transfected with Survivin-SmBiT (Surv-Sm) and LgBiT-PI3K (Lg-PI3K). When 
interacting in the cell, the two subunits form a functional luciferase resulting in a detectable 
luminescence signal (A). (B) 24 h after transfection with the NanoBiT constructs, cells were irradiated 
with 4 Gy followed by the addition of Nano-Glo® Live Cell Reagent and luminescence measurement at 
1 h after IR. As controls, cells were mock treated (grey) or transfected with HaloTag plasmid instead of 
the SmBiT construct (green with black stripes). As a positive control, Survivin fused to SmBiT and LgBiT 
was used to show dimerization of Survivin (white). (C) Internal assay negative and positive controls 
were used to verify the assay’s functionality. Data represent means ± SEM from at least three 
independent experiments. Statistical significances are indicated by asterisks: * p < 0.05, *** p < 0.001. 
 
Assessment of the well established Survivin-Survivin interaction measurements confirmed the 
ability of Survivin to form stable homodimers. Besides, an interaction between Survivin and 
the PI3K domain of DNA-PKcs was evident in non-irradiated and irradiated (4 Gy) cells, 
indicated by a significantly increased luminescence signal compared to mock treated cells and 
HaloTag control (Figure 21B). These results thus confirm the findings of the pulldown 
experiments by showing an interaction between Survivin and the kinase domain of DNA-PKcs 
in HEK-293T cells.  
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Survivin binds to the PI3K domain of DNA-PKcs in flow cytometry-based FRET  
As a third method, the interaction of Survivin with the PI3K domain of DNA-PKcs was 
analysed via Förster resonance energy transfer (FRET). FRET is based on energy transfer 
between two fluorophores. In this assay, an excited donor fluorophore can transfer energy to 
an acceptor fluorophore, if the fluorophores are within a distance of 10 nm. Furthermore, it is 
essential that the emission spectrum of the donor fluorophore and the absorption spectrum of 
the acceptor fluorophore are overlapping (Clegg, 1995; Jares-Erijman and Jovin, 2003; Sun et 
al., 2013). YFP and CFP fulfil these requirements and were fused to the potential interaction 
partners Survivin and the kinase domain (PI3K) of DNA-PKcs (Figure 22).  
 
Figure 22: Schematic representation of the Förster resonance energy transfer (FRET) principle. FRET is 
based on the energy transfer from an excited donor fluorophore to an acceptor fluorophore. The two 
fluorophores have to be within a distance of 10 nm or less for this energy transfer to work. In addition, 
the emission spectrum of the donor fluorophore and the absorption spectrum of the acceptor 
fluorophore must be overlapping. As fluorophores, cyan fluorescent protein (CFP) or yellow fluorescent 
protein (YFP) were fused to the interaction partners Survivin and PI3K. (Figure modified from (Simkova 
and Stanek, 2012)) 
 
At first, CFP and YFP were fused to the N- and C-termini of Survivin and PI3K to unravel the 
optimal combination to use in flow cytometry-based FRET. After transfection of the different 
fusion constructs in HEK-293T cells, their expression was confirmed by western blotting 
(Figure 23A) and fluorescence microscopy (Figure 23B).  
Western blotting confirmed expression of Survivin fusion constructs with signals 
corresponding to the expected molecular weight (44/45 kDa). In contrast, expression of the 
PI3K constructs was lower compared to Survivin and only CFP/YFP fused to the N-terminus of 
PI3K resulted in a band of the correct molecular weight (59 kDa). The C-terminal fusion of 
CFP and YFP resulted in degradation of the protein, indicated by a second (smaller) protein 
band in the experiment (Figure 23A). Fluorescence microscopy of the CFP and YFP fusion 
constructs showed localisation of both constructs in the cytoplasm and in the nucleus (Figure 
23B). 
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Figure 23: Expression of CFP/YFP-Survivin/-PI3K fusion constructs in HEK-293T cells. (A) Western blot 
confirmation of expression of N- and C-terminal CFP/YFP-Survivin and CFP/YFP-PI3K constructs. GFP 
antibodies were used to detect recombinant protein expression, β-actin served as loading control. (B) 
Immunofluorescence staining of Survivin/PI3K fusion constructs using GFP (for CFP constructs) and YFP 
antibodies. Nuclei were stained with DAPI (blue).  
 
The gates for flow cytometry-based FRET analyses were set according to Banning and 
colleagues (Banning et al., 2010) and are exemplarily shown in Figure 24. At first, living cells 
were separated from cell debris by forward scatter (FSC) and sideward scatter (SSC) (Figure 
24A1+B1) followed by separation of the FRET signal from CFP, YFP and background signals 
(Figure 24A2+B2). The four quadrants in Figure 24A2+B2 separate the four signals of YFP 
fluorescence (upper-left quadrant), CFP fluorescence (lower-right quadrant), cells that are 
CFP and YFP positive (upper-right quadrant) and the background signal (lower-left 
quadrant). Another important gating step was necessary because YFP, when excited at 
405 nm, exhibited some emission in the FRET-channel, resulting in false-positive FRET-
positive cells (Figure 24A3+B3). Finally, FRET was plotted versus CFP and a triangular gate 
was created to determine the number of FRET-positive cells (Figure 24A4+B4). In this gate, 
the actual FRET signal is separated from the CFP signal again, because both are excited at the 
same wavelength. The gates were set using cells co-transfected with CFP and YFP only, 
indicating FRET-negative cells as well as cells transfected with a CFP-YFP fusion protein 
indicating FRET-positive cells.  
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Figure 24: Exemplary gating strategy for FRET interaction analyses with flow cytometry. (A) Gating for 
the formation of Survivin homodimers. (B) Gating for PI3K-Survivin interaction analysis. SSC: sideward 
scatter; FSC: forward scatter; YFP: yellow fluorescent protein; CFP: cyan fluorescent protein; FRET: 
Förster resonance energy transfer. 
 
Transfection of HEK-293T cells with the CFP-YFP fusion construct resulted in 100% FRET-
positive cells. In contrast, mock-treated cells and co-transfection of CFP and YFP showed less 
than 1% FRET-positive cells. Dimerization of Survivin could be confirmed by 75% FRET-
positive cells and co-transfection with Survivin and the PI3K domain of DNA-PKcs showed 
approximately 18% FRET-positive cells. As opposed to this, co-transfection of Survivin and the 
alternative HEAT1 or FATC domain of DNA-PKcs showed no or very few FRET-positive cells 
(Figure 25B).  
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Figure 25: Flow cytometry-based FRET measurements show an interaction between Survivin and the 
PI3K domain of DNA-PKcs. (A) Schematical representation of the used constructs in the FRET 
measurements. Negative controls were co-transfections of CFP and YFP as well as transfections of the 
PI3K or Survivin fusion constructs alone. Positive controls were a CFP-YFP fusion construct and the 
formation of Survivin homodimers. (B) FRET-positive cells in percent of controls (grey), Survivin 
dimerization (white) and interactions of Survivin with different domains of DNA-PKcs, including PI3K, 
HEAT1 and FATC (green). Data represent means ± SEM from at least three independent experiments. 
FRET measurements were performed by Melanie Hoffmann. 
 
In summary, these findings could provide evidence for an interaction of Survivin with the 
kinase domain (PI3K) of DNA-PKcs with three independent methods, giving further insights in 
the role of Survivin in the NHEJ DNA double-strand break repair pathway.  
 
4.4. The impact of Survivin on the activity of DNA-PK 
After having established that Survivin interacts with the kinase domain of the DNA-PKcs, we 
finally performed experiments to gain knowledge about the functional properties of this 
interaction. For the analysis of DNA-PKcs kinase activity, autophosphorylation at serine 2056 
(Ser2056, S2056) was assessed by western blotting and phosphorylation of a p53-derived 
target peptide was tested by a SignaTECT kinase assay.  
 
Controls: 
Survivin PI
3K
 
PI
3K
 
Survivin 
Survivin Survivin 
Interaction measurement: 
A B 
YFP CFP 
CFP -- YFP 
mo
ck
CF
P +
 YF
P
CF
P-
YF
P
Su
rvi
vin
 + 
Su
rvi
vin
Su
rvi
vin
 + 
PI3
K-
DN
A-
PK
cs
Su
rvi
vin
 + 
HE
AT
1-D
NA
-P
Kc
s
Su
rvi
vin
 + 
FA
TC
-D
NA
-P
Kc
s
0
25
50
75
100
FR
ET
 p
os
iti
ve
 c
el
ls
 (%
)
 Results 74 
4.4.1. Survivin depletion modulates autophosphorylation of DNA-PKcs on serine 
2056 
As compared to siRNA control transfected cells, autophosphorylation of Ser2056 was 
decreased after siRNA-mediated knockdown of Survivin in mock irradiated and irradiated 
(4 Gy) SW480 colorectal cancer cells (Figure 26A). This decrease was further confirmed in 
LN-229 glioblastoma cells (Figure 26B).  
 
 
Figure 26: Autophosphorylation of serine 2056 of DNA-PKcs is modulated by Survivin. SW480 (A) and 
LN-229 (B) cells irradiated with 4 Gy 48 h after transient transfection with control siRNA (siCtrl) or 
Survivin-directed siRNA (siSurv). 1 h after irradiation, cell lysates were prepared and separated by SDS 
gels. Western blotting was performed using anti-Survivin, anti-DNA-PKcs and anti-pDNA-PKcs S2056 
antibodies. β-actin served as loading control.  
 
These data confirmed former findings on a modulation of DNA-PKcs kinase activity following 
attenuation of Survivin (Capalbo et al., 2010; Reichert et al., 2011).  
 
4.4.2. XIAP binding site of Survivin is crucial for modulation of DNA-PK kinase 
activity 
Irradiation of SW480 cells stably expressing EGFP, Survivin wt and ΔXIAP deletion mutant of 
Survivin in the presence of non-specific (control siRNA) resulted in an increased DNA-PK 
activity compared to non-irradiated cells (Figure 27, black bars). To analyse the effects of the 
recombinant Survivin constructs, siRNA targeting the endogenous but not the recombinant 
Survivin was used.  
Depletion of endogenous Survivin before irradiation with 4 Gy decreased DNA-PK activity in 
cells expressing the EGFP and ΔXIAP constructs to the level observed in non-irradiated cells. 
By contrast, expression of recombinant Survivin wt rescued DNA-PK activity after siRNA-
mediated knockdown of the endogenous Survivin and irradiation with 4 Gy (Figure 27, green 
bars). 
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Figure 27: XIAP binding site deletion mutant of Survivin is not able to restore DNA-PK kinase activity 
upon knockdown of endogenous Survivin. This kinase assay is based on the phosphorylation of a 
biotinylated p53-derived peptide substrate by DNA-PK with [γ-32P] ATP. This biotinylated peptide 
substrate was then spotted on a biotin capture membrane for detection of the incorporated 32P into 
the p53-derived peptide. SW480 cell stably expressing EGFP, Survivin wt and ΔXIAP were transiently 
transfected with control siRNA (black) or Survivin siRNA (green) and 48 h thereafter irradiated with 
4 Gy. Nuclear extracts were isolated 1 h after irradiation and SignaTECT kinase assay was performed. Y-
axis shows 32P counts per minute. Data represent means ± SEM from four independent experiments. 
Statistical significances are indicated by asterisks: * p < 0.05. 
 
Summing up, in our functional assays we showed that a knockdown of Survivin decreased 
autophosphorylation of DNA-PKcs at Ser2056 as well as the activity of DNA-PK in the 
Survivin-ΔXIAP mutant expressing cells. These results indicate that the interaction between 
DNA-PKcs and Survivin is modulating DNA-PK activity in irradiated cells.  
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5. Discussion 
Survivin is dramatically overexpressed in the majority of solid and hematologic human 
tumours. This has been reported in studies analysing many different tumour entities, whereas 
the respective normal tissues did not show Survivin expression (Altieri, 2003b; Miura et al., 
2011; Rodel et al., 2012). While in non-cancerous cells, Survivin expression is controlled in a 
cell cycle-dependent manner with a peak in mitosis (Li et al., 1998) and a prominent increase 
in G2/M phase (Altieri, 2001; Lens et al., 2006), gene expression of Survivin in tumour cells is 
additionally mediated by cell cycle-independent mechanisms (Li et al., 2010; Xia and Altieri, 
2006). These mechanisms can activate transcription, e.g. by demethylation of CpG islands in 
the promoter region (Hattori et al., 2001) or increased promoter activity by oncologic 
transcription factors (Li and Altieri, 1999) as well as negatively regulate transcription, for 
instance by wild type tumour suppressor p53 (Xia and Altieri, 2006). Besides transcriptional 
regulation, Survivin is also post-transcriptionally regulated by ubiquitylation, de-
ubiquitylation (Vong et al., 2005; Zhao et al., 2000) and phosphorylation (Colnaghi and 
Wheatley, 2010; Dohi et al., 2007; O'Connor et al., 2002; Wheatley et al., 2007).  
The elevated levels of Survivin in tumours were not only associated with a higher risk of 
tumour recurrences and lymph node metastases, but also with a shortened survival of patients 
with many different tumour entities (Altieri, 2003b; Capalbo et al., 2007; Mita et al., 2008; 
Rodel et al., 2012; Sprenger et al., 2011). Due to its diagnostic relevance, Survivin has been 
proposed as prognostic factor (Rodel et al., 2012). Besides, Survivin was reported to be 
associated with a lowered success to standard anti-cancer therapy and to comprise a chemo- 
and radiation resistance factor (Asanuma et al., 2000; Chakravarti et al., 2004; Rodel et al., 
2003). In line with that, Survivin attenuation resulted in a radiosensitization of tumour cells 
in vitro and in vivo. In vitro studies using glioblastoma, colorectal carcinoma, hepatocellular 
carcinoma and non-small cell lung cancer (NSCLC) cells showed a decreased clonogenic 
survival upon Survivin depletion and ionizing radiation accompanied by increased apoptosis 
and induction of a G2/M cell cycle arrest (Rodel et al., 2011; Rodel et al., 2012).  
Apart from participating in cell division and cytokinesis as a member of the chromosomal 
passenger complex and its role in apoptosis inhibition, Survivin is a nodal protein that is 
involved in a multitude of cellular signalling pathways and transcriptional networks in tumour 
cells (Altieri, 2008). A striking feature of Survivin is its ability to co-operate with a variety of 
protein partners including other members of the IAP family (Dohi et al., 2004), heat schock 
proteins (Fortugno et al., 2003; Zhao et al., 2000), microtubules (Giodini et al., 2002; Rosa et 
al., 2006), p53 (Hoffman et al., 2002) as well as DNA repair proteins (Capalbo et al., 2010). 
Important for these protein-protein interactions are the different domains and binding sites of 
Survivin. In order to gain more information about the different protein interactions, further 
investigation of the different domains and binding sites of Survivin were seriously required. In 
a recent project in our group, deletion mutants of a multitude of Survivin’s domains and 
binding sites were analysed regarding to cell cycle changes, apoptosis, 
invasion/transmigration, clonogenic survival and γH2AX/53BP1 foci detection as a marker for 
the induction and repair of DNA double-strand breaks. Deletion of the BIR domain as well as 
XIAP, microtubule and Hsp90 binding sites resulted in an arrest in the G2/M cell cycle phase, 
increased apoptosis and reduced transmigration ability in SW480 colorectal cancer cells. 
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Moreover, radiation survival was decreased and numbers of residual (24 h) γH2AX/53BP1 
foci were elevated in the XIAP binding site and BIR domain deletion mutant, indicating that 
the XIAP binding site of Survivin may be essential for clonogenic survival after irradiation as 
well as the modulation of DNA repair (Petraki, 2014). 
The aim of this present study was to further unravel the molecular mechanism underlying a 
Survivin-mediated modulation of DNA repair. In order to achieve that goal, it was crucial to 
characterise the interaction between Survivin and DNA-PKcs, which is a major enzyme of the 
non-homologous end-joining repair pathway (NHEJ).  
In a first set of experiments, the impact of Survivin on radiation-induced DNA damage repair 
was analysed in SW480 colorectal cancer cells by immunofluorescence staining of the 
phosphorylation of the histone variant H2AX on serine 139 (γH2AX) and p53-binding 
protein 1 (53BP1) recruitment as markers for the presence of DNA DSBs. γH2AX/53BP1 foci 
were quantified 15 min and 30 min after irradiation with 1 Gy as well as 24 h after irradiation 
with 4 Gy. Quantification at early time points (15 min, 30 min) showed a significant increase 
of nuclear foci after irradiation with 1 Gy upon knockdown of Survivin in SW480 cells (Figure 
10C). Residual DNA damage (24 h) was also significantly increased upon Survivin depletion 
and irradiation with 4 Gy (Figure 10B). These findings indicate a hampered double-strand 
break repair in Survivin-depleted cells, both, at short time points and 24 h after irradiation. 
These results are consistent with the literature, where a similar effect after Survivin 
knockdown has been observed in SW480 and LN-229 glioblastoma cells (Capalbo et al., 2010; 
Reichert et al., 2011). In the present study, a DNA repair modulating effect of Survivin 
expression was further confirmed using an A2780 ovarian cancer line (Figure 11), indicating 
that modulation of DNA damage repair by Survivin may comprise a more general 
functionality of the protein. 
In order to identify the DNA DSB repair pathway in which Survivin is involved, γH2AX/53BP1 
foci have been quantified in the BRCA2-deficient ovarian cancer cell line OVSAHO. BRCA2 
has a crucial role in the HR repair pathway by loading Rad51 to resected DNA regions 
(Sorensen et al., 2005) and due to the homozygous deletion of BRCA2 (Domcke et al., 2013), 
the OVSAHO cell line it is not able to perform HR. Survivin knockdown and irradiation with 
4 Gy resulted in significantly increased residual DNA damage after 24 h (Figure 12B). The 
number of γH2AX/53BP1 foci at early time points (15 min, 30 min) after IR with 1 Gy was 
significantly increased in Survivin-depleted cells, too (Figure 12C). The comparable effects, 
resulting from a Survivin knockdown in HR proficient SW480 and LN-229 cells and the HR-
deficient OVSAHO cell line may indicate that Survivin is involved in regulation of a DNA DSB 
repair pathway other than HR.  
These findings are a contradictory to the literature. Survivin has recently been shown to 
participate in HR. By using the small-molecule Survivin inhibitor YM155, Qin and colleagues 
were able to show a suppressed HR repair in human esophageal squamous cell carcinoma 
(ESCC) (Qin et al., 2014). Besides, Survivin was found to participate in HR by modulating the 
protein expression of Rad51 and MUS81 in breast cancer cells (Vequaud et al., 2016). In the 
present study, a contribution of Survivin in HR was thus further analysed by a real-time PCR-
based HR assay, which is often used to measure HR efficiency in cells upon different 
treatments (Christmann et al., 2017; Maachani et al., 2015; Ohba et al., 2014). In this assay, 
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HR efficiency was quantified by co-transfection of two plasmids, each with a different 
mutation in its lacZ coding region. A recombination of these two plasmids leads to a 
recombined plasmid with a functional lacZ sequence which can be quantified with specific 
primers via real-time PCR (Ohba et al., 2014). In contrast to the literature cited above, a 
significantly decreased HR efficiency after Survivin knockdown and DSB induction by 
irradiation with 4 Gy could not be observed in SW480 colorectal cancer cells (Figure 13). 
These discrepancies could result from the different cell lines that were used in these studies. 
Moreover, in these studies the Survivin suppressant YM155 was used. This molecule, 
however, is also reported to directly impact on DNA double-strand break repair (Hong et al., 
2017) and thus may facilitate some of the effects reported. 
According to preceeding studies, Survivin accumulates in the nucleus following irradiation. 
During the regulation of DNA repair it interacts with DNA-PKcs and Ku70, two important 
proteins of the NHEJ DSB repair pathway (Capalbo et al., 2010; Reichert et al., 2011). In this 
study, immunoprecipitation experiments confirmed the binding of recombinant Survivin wt to 
DNA-PKcs in both SW480 colorectal cancer (Figure 15) and LN-229 glioblastoma cells (Figure 
16). By contrast, Survivin lacking the XIAP binding site did not precipitate with DNA-PKcs. As 
a result, the XIAP binding site of Survivin is not only important for the formation of a 
Survivin-XIAP complex that is inhibiting apoptosis (Dohi et al., 2004), but also for the 
interaction with DNA-PKcs in order to regulate DNA double-strand break repair via NHEJ. The 
decreased radiation survival and the elevated numbers of residual γH2AX/53BP1 foci in the 
XIAP binding site deletion mutant of Survivin that was described earlier (Petraki, 2014), 
might at least in part, be explained by the inability of this mutant to interact with DNA-PKcs. 
Since the XIAP binding site is a part of the larger BIR domain of Survivin, this is in line with 
the general function of the BIR domains of all IAPs as mediator of protein-protein interactions 
(Srinivasula and Ashwell, 2008).  
Methodically, immunoprecipitations were perfomed with anti-DNA-PKcs antibodies. However, 
the vice versa experiment using anti-Survivin antibodies did not work. The reason for this may 
be the huge molecular weigth of DNA-PKcs. Regarding its considerable weight of 470 kDa 
compared to smaller Survivin-EGFP construct (44 kDa) it is possible that during an 
interaction, DNA-PKcs sterically hinders the binding of the antibody to the protein. Therefore, 
precipitation of the Survivin-EGFP/DNA-PKcs complex with an anti-Survivin antibody might 
not be possible. In order to make sure that the interaction of Survivin and DNA-PKcs is not 
EGFP-mediated, EGFP-expressing cells were used as a control. In the immunoprecipitation 
experiment in SW480 cells, EGFP in the input runs slightly below the light chain of the 
antibody that is present in the IP lanes. However, EGFP did not bind to precipitated DNA-PKcs 
(Figure 15). 
After showing a direct involvement of the XIAP binding site of Survivin in the interaction with 
DNA-PKcs, the next step was to investigate possible binding regions of DNA-PKcs mediating 
the interaction with Survivin. For Aurora-B, another well-established interaction partner of 
Survivin in terms of cell cycle regulation, it was shown that Survivin binds to its catalytic 
domain (Chen et al., 2003). In the presence of Survivin, histone H3 is phosphorylated more 
efficiently by Aurora-B than in the absence of Survivin. Furthermore, a decreased Aurora-B 
kinase activity in cells lacking Survivin indicates that Survivin stimulates Aurora-B kinase 
activity in order to help Aurora-B targeting its substrates during the cell cycle (Chen et al., 
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2003). In analogy, we next analysed a putative interaction of Survivin with the kinase domain 
of DNA-PKcs. Indeed, by using GST pulldown assay (Figure 18), NanoLuc Binary Technology 
(NanoBiT®) complementation assay (Figure 21) and flow cytometry-based Förster resonance 
energy transfer (Figure 25), binding of Survivin to the kinase domain (PI3K) of DNA-PKcs was 
observed. Furthermore, in silico docking analysis was used to gain a bioinformatic perspective 
on the interaction between Survivin and DNA-PKcs. 
At first, a glutathione S-transferase (GST) pulldown assay was performed using lysates of 
SW480 colorectal cancer cells. After pulldown of GST-PI3K, both Survivin-EGFP and 
endogenous Survivin were found binding to the GST-PI3K fusion construct (Figure 18A). By 
using EGFP and GST controls, it was ruled out that the interaction was induced by the 
presence of the tags (Figure 18A). However, endogenous Survivin was expected being pulled 
down by GST-PI3K also in cells expressing EGFP, which did not. The reason for this remains 
unclear, but the amount of GST-PI3K-bound endogenous Survivin might have been under the 
detectable minimum of the western blot. In GST control pulldown assays, Survivin was not 
detectable, hence, we suggest a specific interaction between Survivin and the PI3K domain of 
DNA-PKcs. These results were confirmed by using FLAG-tagged Survivin (Figure 18B). The 
bacterial expression of GST-PI3K turned out to be fairly weak, instead several degradation 
products could be detected (Figure 17B). The fact that an interaction of the Survivin fusion 
constructs with PI3K was found although expression of GST-PI3K was weak, suggests that it is 
indeed a specific interaction.  
To confirm the results of the GST pulldown assay, the two-subunit luciferase-based NanoBiT 
complementation assay was performed but in contrast to the GST pulldown assay, the 
NanoBiT assay was performed in HEK-293T cells. In preliminary experiments using different 
transfection reagents, transfection efficiency in HEK-293T cells was found to be substantially 
higher than in SW480 cells and therefore this cell line was chosen for this interaction assay. 
Since it measures the luciferase signal generated only from double-transfected cells, a high 
transfection efficiency is essential for obtaining reproducible results. A discrimination of non-
transfected cells was not possible prior to measuring luminescence. To verify the specificity of 
the NanoBiT assay, a negative control using co-transfection of the LgBiT fusion construct and 
a HaloTag construct was used. Interaction of Survivin-SmBiT and LgBiT-PI3K was significantly 
increased compared to HaloTag and single fusion controls, therefore the interaction can be 
considered specific (Figure 21B).  
Lastly, the interaction of Survivin with the PI3K domain of DNA-PKcs was analysed via Förster 
resonance energy transfer. Here, YFP and CFP fluorescence tags were fused to the interaction 
partners Survivin and the kinase domain (PI3K) of DNA-PKcs. When measuring the CFP-YFP 
fusion construct as well as CFP and YFP negative controls for the establishment of the flow 
cytometric based FRET assay, the results were as expected. The CFP-YFP fusion construct 
resulted in nearly 100% FRET-positive cells, proving the functionality of this assay. False 
positive cells created by a co-localisation of the fluorophores in the cell without protein 
interactions could be ruled out because co-transfection of the CFP and YFP plasmids did not 
show any interaction (Figure 25). Another proof of principle control was the co-transfection of 
Survivin fused to CFP and YFP, resulting in approximately 75% FRET-positive cells. This 
confirms the published ability of Survivin forming homodimers (Chantalat et al., 2000; 
Verdecia et al., 2000). The decreased number of FRET-positive cells compared to the CFP-YFP 
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fusion construct, suggests that not all Survivin proteins are forming homodimers. Another 
explanation could be that endogenous Survivin forms dimers with CFP- or YFP-tagged 
Survivin, which would not be detected as a FRET-positive signal. The analysis of the 
interaction between Survivin and the kinase domain of DNA-PKcs (PI3K) resulted in 
approximately 18% FRET-positive cells. As opposed to this, co-transfection of Survivin and the 
HEAT1 or FATC domain of DNA-PKcs showed no or very few FRET-positive cells (Figure 25). 
These findings support the assumption that the interaction of Survivin with DNA-PKcs is 
indeed mainly mediated by the kinase domain of DNA-PKcs.  
One remaining question is why the interaction between Survivin and the PI3K domain of 
DNA-PKcs was rather weak in both, NanoBiT and FRET, compared to the positive controls of 
the respective assay. One explanation for the weak interaction might be the cellular 
localisation of the two fusion proteins. Fluorescence microscopy of the CFP and YFP fusion 
constructs indicated localisation of both constructs in the cytoplasm and in the nucleus 
(Figure 23B). Since DNA-PKcs is a DNA repair protein, it is mainly localised in the nucleus 
(Koike et al., 1999) and accordingly the interaction with Survivin is considered most likely in 
the nucleus as well. It is known that Survivin accumulates in the nucleus shortly after 
irradiation (Capalbo et al., 2010), which supports this hypothesis. The mechanism behind the 
accumulation of Survivin in the nucleus is not yet fully understood, however, it could be 
hampered by the fusion of Survivin to the fluorescence tags. Additionally, the PI3K-DNA-PKcs 
fusion protein is not actively transported to the nucleus because its sequence does not contain 
a nuclear localisation signal (NLS). As a result, both, the PI3K and the Survivin fusion proteins 
are only partly present in the nucleus. An interaction in the cytoplasm is probably not possible 
due to lack of nuclear co-factors that are involved in or needed for the interaction. Another 
factor that could negatively affect the interaction between Survivin and the PI3K domain of 
DNA-PKcs is the absence of the neighbouring FAT and FATC domains as well as the HEAT 
repeats. Although Survivin does not bind to other tested single domains of DNA-PKcs (HEAT1 
and FATC, Figure 25B) except PI3K, these other domains could be beneficial for an 
interaction of Survivin with the PI3K domain. According to the literature, the different parts of 
DNA-PKcs have a different role on its activity (Davis et al., 2013). The HEAT repeats probably 
mediate protein-protein interactions (Andrade and Bork, 1995; Brewerton et al., 2004; Jiang 
et al., 2006) and the FATC domain was found to be required for kinase activity (Beamish et 
al., 2000). The presence of these domains may further increase the ability of the PI3K domain 
and Survivin to form a comlex.  
A bioinformatic modelling approach for the interaction of Survivin with DNA-PKcs was 
performed using the programs Schrödinger Suite and PatchDock. Before the docking analysis, 
pre-processing steps were performed to obtain more native structures of the proteins. After 
the docking analysis, the best-docked poses were post-processed and refined by side-chain 
optimization and rigid-body minimization. Interactions between residues were determined 
according to their binding energies (ΔG) and distances. Interaction pairs with higher ΔG 
values and distances <5 Å between side chain hydrogen atoms were qualified as potential 
interactors (see chapter 3.2.21 for a more detailed description of the docking analysis).  
The protein docking analysis confirmed binding of Survivin to the PI3K kinase domain of 
DNA-PKcs. However, for this interaction Survivin must be present in its dimerized form. In 
order to mimic more natural conditions of the interaction, we aimed to find out whether the 
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interaction of Survivin with the kinase domain of DNA-PKcs is also happening in the presence 
of the whole DNA-PKcs protein. Therefore, protein docking analysis was performed, 
investigating the interaction of Survivin with the entire DNA-PKcs protein (Figure 28). 
 
 
Figure 28: Protein docking analysis show an interaction between Survivin and DNA-PKcs. Before the 
docking analysis, pre-processing steps were performed to obtain more native structures of the proteins. 
After the docking analysis, the best-docked poses were then post-processed and refined by side-chain 
optimization and rigid-body minimization. After that, interactions between residues were determined 
according to their binding energies (ΔG) and their distances. Interaction pairs with higher ΔG values 
and distances <5 Å between side chain hydrogen atoms were qualified as potential interactors. Cyan: 
Survivin; red: kinase domain (PI3K) of DNA-PKcs; light brown: the rest of DNA-PKcs. Protein model was 
created using the Chimera program (University of California, San Francisco, CA, USA). Protein docking 
analysis was performed by Ömer Güllülü. 
 
The protein docking analysis resulted in the hypothesis that Survivin is only able to bind to 
DNA-PKcs in its dimerized form (Figure 28), although this assumption has not yet been 
analysed experimentally.  
For the dimerization of Survivin, its N-terminal region including the BIR domain is sufficient 
(Chantalat et al., 2000). The exact function of the Survivin dimerization is not yet fully 
understood, however, it could have a potential role in stabilizing Survivin. In terms of its role 
in the organisation of the microtubule organizing centres (MTOC), the orientation and length 
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of the two C-terminal helices of the Survivin dimer suggest that Survivin could bridge proteins 
participating in the organization of the MTOC (Verdecia et al., 2000). Considering the need of 
dimerized Survivin for the interaction with DNA-PKcs, it could possibly have a similar 
bridging function in DNA double-strand break repair. Dimerization is also important for 
Survivin to remain in the nucleus. The reason for that is the monomer-specific NES of 
Survivin, whose hydrophobic residues are occupied in its homodimer form. With these 
occupied residues, Crm1, the main export protein in mammalian cells that facilitates the 
transport of RNA and proteins across the nuclear membrane to the cytoplasm, is no longer 
able to shuttle Survivin (Engelsma et al., 2007; Knauer et al., 2007; Stauber et al., 2006). In 
summary, dimerization of Survivin modulates cytoplasmic access of the protein and by being 
present in its dimerized form Survivin is able to accumulate in the nucleus where it can 
interact with DNA-PKcs. 
Functionally, Survivin has been shown to impact on Ser2056 autophosphorylation of DNA-
PKcs as well as DNA-PK kinase activity after irradiation (Capalbo et al., 2010; Reichert et al., 
2011). In this study, a reduction of Ser2056 autophosphorylation after siRNA-mediated 
Survivin attenuation followed by irradiation was confirmed in SW480 colorectal cancer and 
LN-229 glioblastoma cells (Figure 26). Besides, irradiation of SW480 cells stably expressing 
EGFP, Survivin wt and ΔXIAP deletion mutant of Survivin resulted in an increased DNA-PK 
activity compared to non-irradiated cells (Figure 27). Additionally, siRNA targeting the 
endogenous Survivin was used to analyse the effects of the recombinant Survivin mutants on 
the DNA-PK activity. Depletion of endogenous Survivin followed by irradiation decreased 
DNA-PK kinase activity to the level observed in non-irradiated cells expressing the EGFP and 
ΔXIAP construct. Only the recombinant Survivin wt was able to rescue DNA-PK activity after 
siRNA-mediated attenuation of endogenous Survivin and irradiation (Figure 27). These 
results indicate the importance of the XIAP binding site of Survivin for DNA-PK kinase activity 
in irradiated cells. Without its XIAP binding site, Survivin is not able to interact with DNA-
PKcs in order to increase DNA-PK activity after irradiation. 
In this study we show that Survivin is not only interacting with DNA-PKcs but directly binds to 
its kinase domain (Figure 29). This interaction between Survivin and DNA-PKcs is important 
for DNA-PK kinase activity in irradiated cells. However, this does not mean that Survivin 
depletion leads to a loss of the NHEJ repair pathway. Knockdown of Survivin only modulates 
DNA repair capacity. Also, DNA-PK activity is just decreased after Survivin knockdown and 
not completely depleted. All in all, the role of Survivin in the NHEJ repair of irradiation-
induced DSBs is more of modulating nature, comparable to its role in the chromosomal 
passenger complex where it enhances the kinase activity of Aurora-B and targets it to its 
substrate (Chen et al., 2003). Depletion of Survivin in HeLa cells causes mislocalisation of 
Aurora-B followed by a decreased Aurora-B activity and increased cytokinesis defects (Chen et 
al., 2003). This fits to the impact of Survivin knockdown on DNA-PKcs with decreased kinase 
activity and a hampered DNA DSB repair. Regarding this, the role of Survivin might be very 
similar for both kinases, as a bridging protein targeting both, Aurora-B and DNA-PKcs to its 
substrates.  
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Figure 29: Survivin as a modulator of the NHEJ double-strand break repair pathway. In this schematic 
illustration Survivin is shown to translocate to the nucleus following irradiation in order to modulate the 
NHEJ double-strand break repair pathway via binding to the kinase domain (PI3K) of DNA-PKcs in its 
dimerized form. Thereby, the XIAP binding site of Survivin is crucial for binding to DNA-PKcs and its 
kinase activity. 
 
The different expression in tumours compared to their respective normal tissue as well as the 
involvement in apoptosis inhibition, maintaining cancer cell viability and its robust correlation 
with poor patient prognosis, renders Survivin a promising target for molecular cancer therapy 
(Mita et al., 2008; Peery et al., 2017; Pennati et al., 2008). In line with that, a variety of 
Survivin-targeting strategies such as mRNA antagonization, siRNAs, small molecule inhibitors 
or Survivin-based immunotherapy have been developed (Mita et al., 2008; Peery et al., 2017). 
Despite strong preclinical data for some inhibitors, only limited response of currently available 
therapeutics targeting Survivin in clinical trials was found (Peery et al., 2017).  
The improved understanding of Survivin’s role in the NHEJ repair of radiation-induced DSBs 
shows once more the importance of Survivin for tumour cells. Targeting Survivin and thereby 
achieving hampered DNA repair in the tumour tissue could, especially in combination with 
radiotherapy, may improve the clinical outcome of the patients. One key for successful 
targeting of Survivin in order to inhibit DNA repair could be a homodimerization inhibitor. By 
using such an inhibitor, dimerization could be prevented and Survivin would be exported 
from the nucleus to the cytoplasm. By preventing the interaction between Survivin and DNA-
PKcs using an inhibitor targeting the exact interacting amino acids, a benefit for the patients 
may be achieved. Although the exact interacting amino acids are yet to be identified.  
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In conclusion these findings for the first time indicate that Survivin not only interacts with 
DNA-PKcs but directly binds to its kinase domain. Besides it modulates DNA-PKcs kinase 
activity and as a consequence repair of radiation induced DNA double-strand breaks. These 
results add a further facet to the plethora of functions exerted by the nodal protein Survivin in 
the cellular radiation response in cancer cells. 
 
Future prospects 
For future perspectives, the interaction between Survivin and DNA-PKcs must be further 
investigated by looking more closely at the sites of interaction of the two proteins. By using a 
bioinformatic protein docking approach, the exact amino acids of Survivin that are involved in 
its interaction with DNA-PKcs, more specifically its PI3K domain could be identified. In the 
next step, single amino acids or a combination of various amino acids within the binding site 
could be mutated to check whether an interaction of the two proteins would still be possible. 
Ideally, one or a combination of several mutations would eliminate the interaction while wild 
type Survivin could still interact. 
Preliminary data including mass spectrometry-based quantitative proteomics following stable 
isotope labelling with amino acids in cell culture (SILAC) further revealed potential 
interaction partners of Survivin, such as Parp1 and XRCC1. Both of these proteins are 
important factors in the MMEJ (also called alternative end-joining) (Iliakis et al., 2015). An 
interaction between Survivin and Parp1 and/or XRCC1 could imply its involvement in a 
second end-joining DSB repair pathway. Interaction with two factors of this pathway would 
suggest once more a protein bridging function of Survivin. First immunoprecipitation analysis 
already confirmed binding of Survivin to Parp1, although this interaction does not seem to be 
dependent of Survivin’s XIAP binding site (data not shown). Considering this, Survivin’s role 
could go beyond NHEJ double-strand break repair, which could be worth further 
investigation.  
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7. Appendix 
 
7.1. DNA sequences 
 
Survivin wt 
GGTGCCCCGACGTTGCCCCCTGCCTGGCAGCCCTTTCTCAAGGACCACCGCATCTCTACATTCA
AGAACTGGCCCTTCTTGGAGGGCTGCGCCTGCACCCCGGAGCGGATGGCCGAGGCTGGCTTCA
TCCACTGCCCCACTGAGAACGAGCCAGACTTGGCCCAGTGTTTCTTCTGCTTCAAGGAGCTGGA
AGGCTGGGAGCCAGATGACGACCCCATAGAGGAACATAAAAAGCATTCGTCCGGTTGCGCTTT
CCTTTCTGTCAAGAAGCAGTTTGAAGAATTAACCCTTGGTGAATTTTTGAAACTGGACAGAGAA
AGAGCCAAGAACAAAATTGCAAAGGAAACCAACAATAAGAAGAAAGAATTTGAGGAAACTGCG
GAGAAAGTGCGCCGTGCCATCGAGCAGCTGGCTGCCATGGAT 
 
Survivin-ΔXIAP 
ATGGGTGCCCCGACGTTGCCCCCTGCCTGGCAGCCCTTTCTCTCTAGAGCCGAGGCTGGCTTCA
TCCACTGCCCCACTGAGAACGAGCCAGACTTGGCCCAGTGTTTCTTCTGCTTCAAGGAGCTGGA
AGGCTGGGAGCCAGATGACGACCCCATAGAGGAACATAAAAAGCATTCGTCCGGTTGCGCTTT
CCTTTCTGTCAAGAAGCAGTTTGAAGAATTAACCCTTGGTGAATTTTTGAAACTGGACAGAGAA
AGAGCCAAGAACAAAATTGCAAAGGAAACCAACAATAAGAAGAAAGAATTTGAGGAAACTGCG
GAGAAAGTGCGCCGTGCCATCGAGCAGCTGGCTGCCATGGAT 
 
PI3K-DNA-PKcs 
ATGGAACACCCTTTCCTGGTGAAGGGTGGCGAGGACCTGCGGCAGGACCAGCGCGTGGAGCAG
CTCTTCCAGGTCATGAATGGGATCCTGGCCCAAGACTCCGCCTGCAGCCAGAGGGCCCTGCAG
CTGAGGACCTATAGCGTTGTGCCCATGACCTCCAGGTTAGGATTAATTGAGTGGCTTGAAAATA
CTGTTACCTTGAAGGACCTTCTTTTGAACACCATGTCCCAAGAGGAGAAGGCGGCTTACCTGAG
TGATCCCAGGGCACCGCCGTGTGAATATAAAGATTGGCTGACAAAAATGTCAGGAAAACATGAT
GTTGGAGCTTACATGCTAATGTATAAGGGCGCTAATCGTACTGAAACAGTCACGTCTTTTAGAA
AACGAGAAAGTAAAGTGCCTGCTGATCTCTTAAAGCGGGCCTTCGTGAGGATGAGTACAAGCC
CTGAGGCTTTCCTGGCGCTCCGCTCCCACTTCGCCAGCTCTCACGCTCTGATATGCATCAGCCA
CTGGATCCTCGGGATTGGAGACAGACATCTGAACAACTTTATGGTGGCCATGGAGACTGGCGG
CGTGATCGGGATCGACTTTGGGCATGCGTTTGGATCCGCTACACAGTTTCTGCCAGTCCCTGAG
TTGATGCCTTTTCGGCTAACTCGCCAGTTTATCAATCTGATGTTACCAATGAAAGAAACGGGCC
TTATGTACAGCATCATGGTACACGCACTCCGGGCCTTCCGCTCAGACCCTGGCCTGCTCACCAA
CACCATGGATGTGTTTGTCAAGGAGCCCTCCTTTGATTGGAAAAAT 
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HEAT1-DNA-PKcs 
ATGGCGGGCTCCGGAGCCGGTGTGCGTTGCTCCCTGCTGCGGCTGCAGGAGACCTTGTCCGCT
GCGGACCGCTGCGGTGCTGCCCTGGCCGGTCATCAACTGATCCGCGGCCTGGGGCAGGAATGC
GTCCTGAGCAGCAGCCCCGCGGTGCTGGCATTACAGACATCTTTAGTTTTTTCCAGAGATTTCG
GTTTGCTTGTATTTGTCCGGAAGTCACTCAACAGTATTGAATTTCGTGAATGTAGAGAAGAAAT
CCTAAAGTTTTTATGTATTTTCTTAGAAAAAATGGGCCAGAAGATCGCACCTTACTCTGTTGAAA
TTAAGAACACTTGTACCAGTGTTTATACAAAAGATAGAGCTGCTAAATGTAAAATTCCAGCCCT
GGACCTTCTTATTAAGTTACTTCAGACTTTTAGAAGTTCTAGACTCATGGATGAATTTAAAATTG
GAGAATTATTTAGTAAATTCTATGGAGAACTTGCATTGAAAAAAAAAATACCAGATACAGTTTTA
GAAAAAGTATATGAGCTCCTAGGATTATTGGGTGAAGTTCATCCTAGTGAGATGATAAATAATG
CAGAAAACCTGTTCCGCGCTTTTCTGGGTGAACTTAAGACCCAGATGACATCAGCAGTAAGAGA
GCCCAAACTACCTGTTCTGGCAGGATGTCTGAAGGGGTTGTCCTCACTTCTGTGCAACTTCACT
AAGTCCATGGAAGAAGATCCCCAGACTTCAAGGGAGATTTTTAATTTTGTACTAAAGGCAATTC
GTCCTCAGATTGATCTGAAGAGATATGCTGTGCCCTCAGCTGGCTTGCGCCTATTTGCCCTGCA
TGCATCTCAGTTTAGCACCTGCCTTCTGGACAACTACGTGTCTCTATTTGAAGTCTTGTTAAAGT
GGTGTGCCCACACAAATGTAGAATTGAAAAAAGCTGCACTTTCAGCCCTGGAATCCTTTCTGAA
ACAGGTTTCTAATATGGTGGCGAAAAATGCAGAAATGCATAAAAATAAACTGCAGTACTTTATG
GAGCAGTTTTATGGAATCATCAGAAATGTGGATTCGAACAACAAGGAGTTATCTATTGCTATCC
GTGGATATGGACTTTTTGCAGGACCGTGCAAGGTTATAAAC 
 
FATC-DNA-PKcs 
ATGCTGAAAAAAGGAGGGTCATGGATTCAAGAAATAAATGTTGCTGAAAAAAATTGGTACCCCC
GACAGAAAATATGTTACGCTAAGAGAAAGTTAGCAGGTGCCAATCCAGCAGTCATTACTTGTGA
TGAGCTACTCCTGGGTCATGAGAAGGCCCCTGCCTTCAGAGACTATGTGGCTGTGGCACGAGG
AAGCAAAGATCACAACATTCGTGCCCAAGAACCAGAGAGTGGGCTTTCAGAAGAGACTCAAGT
GAAGTGCCTGATGGACCAGGCAACAGACCCCAACATCCTTGGCAGAACCTGGGAAGGATGGGA
GCCCTG
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